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ABSTRACT 
Objective: Antimicrobial resistance is a global phenomenon which is limiting treatment options for 
common infections resulting in poor clinical outcomes, increased mortality and increased cost of 
healthcare. Antibiotic resistance trends in pathogen-drug combinations stipulated in the Global 
Antimicrobial Surveillance System (GLASS) of the World Health Organization were investigated for 
the period 2011-2015 in the province of KwaZulu Natal, South Africa.  
Methods: Antibiotic susceptibility data from blood, urine, faecal and urethral/cervical samples was 
retrospectively analyzed from six public hospitals. Pathogens included Escherichia coli, 
Streptococcus pneumoniae, Klebsiella pneumoniae, Salmonella spp., Acinetobacter baumannii, 
Staphylococcus aureus, Shigella spp. and N. gonorrhoea. Results were analyzed as MIC50, MIC90, 
percentage resistance, incidence of monitored infections in the population and proportion of non-
susceptible infections per pathogen. Results were also evaluated against South African treatment 
guidelines. Significant differences in resistance proportions by year were identified using the Pearson 
χ2 test. Comparison of MIC50 were analysed using the equality-of-medians test. 
 
Findings:  Urine samples were most abundant (61.22%, n= 33 018) and E. coli (52%) was the most 
common pathogen. Most isolates were multi-drug resistant.  Resistance to third and fourth generation 
cephalosporins and fluoroquinolones increased in K. pneumoniae, E. coli and Shigella spp. over the 5-
year period.  Notable changes in resistance were: K. pneumoniae from blood samples to carbapenems 
(1 – 26%, p< 0.001) and A. baumannii to carbapenems (69% - 50%, p-value not available). 
Susceptibility to antibiotics recommended in treatment guidelines was >50% for most pathogen-drug 
combinations. 
Conclusion: The results of this study show that antibiotic resistance in hospitals in KwaZulu-Natal 
generally increased from 2011 to 2015, although some pathogen-drug combinations showed a plateau 
or decline in resistance necessitating a review of the existing treatment guidelines. To our knowledge, 
this is the first South African report on ABR using GLASS metrics.  There is a need for more 
extensive research in order to build an accurate, comparable picture of ABR in South Africa.  
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Chapter 1 Introduction and Literature Review 
1.1.Introduction 
The increase in the incidence and spread of infectious diseases has led to an increase in the use of 
antimicrobial drugs, in turn causing an increase in antimicrobial resistance (AMR) (Mendelson & 
Matsotso, 2015). The term AMR applies broadly to resistance in all microbial pathogens including 
bacteria, parasites, viruses and fungi while antibiotic resistance (ABR) refers specifically to resistance 
of bacterial pathogens to antibiotics (Shaban, et al., 2013). While ABR is an anticipated result of 
antibiotic use, the spread of resistance is accelerated by preventable factors such as poor infection 
control, irrational antibiotic use and the use of substandard drugs (Hoffman, et al., 2015) (World 
Health Organisation, 2015 (c)) 
ABR is a global concern affecting both developed and developing countries to varying extents. While 
efforts are being made to delineate the incidence, prevalence and mechanisms of ABR, there is a need 
for quality, standardised, comparable data to provide an accurate picture of global trends in ABR 
(World Health Organisation, 2015 (b)).  
The impact of the increasing incidence of ABR is far reaching and if measures are not implemented 
now, the resulting financial burden and mortality due to ABR is projected to be gravely high. The 
World Health Organisation (WHO) has released various publications with suggested action plans in 
order to curb the increase in resistance and in developed regions research around ABR has already 
been established for some years (Hoffman, et al., 2015). 
 ABR surveillance is vital in providing information to guide the development of strategies to curb the 
spread of ABR. Established surveillance programmes such as the Central Asian and Eastern European 
Surveillance of Antimicrobial Resistance (CAESAR) and the European Antimicrobial Resistance 
Surveillance Network (EARS-Net) have provided useful data but are limited in a global context due to 
differences in data collection methods, limited data-sharing and the tendency to focus on specific 
pathogens or regions (World Health Organisation, 2014 (a)). Limited resources in terms of funding, 
laboratory capacity and human resources are obstacles in obtaining useable surveillance data in 
developing countries (Vernet, et al., 2014).  
In May 2015 the Global Action Plan (GAP) on AMR was adopted by the World Health Assembly 
committing WHO member states to developing National Action Plans to combat AMR.  A key 
component of the GAP is surveillance, specifically a uniform system of surveillance and reporting of 
ABR. Subsequently the Global Antimicrobial Surveillance System (GLASS) was developed, aimed 
specifically at ABR in specified bacterial pathogens and the WHO has called on member states to 
implement this programme.  The key to the success of GLASS is in the cooperation of as many 
countries as possible to as large an extent as possible in order to gain baseline data from which further 
strategies can be developed. The GLASS manual for early implementation was published in 2015 and 
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outlines a comprehensive system which aims to provide comparable, validated data which can be 
shared on a global scale in order to guide future interventions against the spread of ABR World 
Health Organisation, 2015(b)). 
In South Africa, AMR in pathogens other than tuberculosis (TB) and Human Immunodeficiency 
Virus (HIV) has increasingly gained attention. Treatable illnesses such as diarrhoeal infections and 
urinary tract infections (UTIs) are among the common conditions burdening our public health system 
(Mendelson & Matsotso, 2015). Budget constraints, especially in public sector healthcare facilities, 
limit the choice of antibiotics to those stipulated in the Standard Treatment Guidelines published by 
the national Department of Health. There is a concern that the susceptibility of pathogens to the 
empiric antibiotics listed in the STGs is limited, which raises concerns about exacerbating resistance, 
wastage of money on ineffective treatment and most importantly, treatment failure. The treatment 
strategies for common infections can be greatly enhanced if informed by current surveillance data.   
(Perovic, et al., 2014) While surveillance studies have been conducted, mainly by academic 
institutions, the data available is not representative enough to guide national strategies. 
1.2. Literature Review 
1.2.1. Surveillance of Antimicrobial Resistance: 
 
Public health surveillance can be defined as the collection and analysis of data in order to monitor and 
manage public health threats and concerns (World Health Organisation, 2017 (a)). The global 
surveillance report published in 2014 by the WHO, showed the burden of AMR in Member States to 
be extensive. The report also illustrated the lack of standardised methodology that limited the 
usefulness of existing surveillance data. Data from hospital based healthcare settings was shown to be 
more readily available than data from community based facilities and there was also a bias in existing 
data in that the samples submitted for sensitivity analyses come from patients who were severely ill 
and were thus more likely to be infected with resistant pathogens. The survey upon which the report 
was based included the bacterial infections that exhibit high levels of resistance and the corresponding 
antibiotics commonly used to treat such infections (World Health Organisation, 2014 (c)).  
While existing surveillance programmes have contributed towards combatting ABR, it is spreading 
such that there is still a deficit in the information required in order to develop evidence-based 
strategies on a global scale. 
Surveillance of ABR is needed to guide clinical interventions to provide an optimal level of care, 
while limiting the spread of resistance. Rapidly spreading resistance is limiting treatment options for 
common infectious diseases, as is the case with the emergence of strains of untreatable gonorrhoea 
(World Health Organisation, 2014 (c)). While comprehensive surveillance of all infections caused by 
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pathogens within a population would be ideal, sentinel surveillance is more realistic and sustainable. 
Sentinel surveillance is conducted on the population of a limited region seen to be representative of 
the rest of the population and can thus provide more detailed data over a longer period of time (World 
Health Organisation, 2016).  
When conducting surveillance on ABR, samples that are representative of both hospital and 
community healthcare settings must be included as different infections are prevalent in each setting. 
While blood stream infections are prevalent in hospitals, gonorrhoea and food-borne diarrhoea are the 
common infections seen in a community health setting and urinary tract infections are prevalent in 
both.  (World Health Organisation.(b), 2015) (World Health Organisation, 2014 (c)).  
In resource limited regions such as Africa, Latin America and the Eastern Mediterranean region there 
are big gaps in information available as they are still in the early stages of combatting ABR  (World 
Health Organisation, 2016). In such settings, there is limited financial capacity and inter-institutional 
collaboration to facilitate the implementation of strategies to curb ABR. In this regard, the Global 
Antimicrobial Surveillance System (GLASS) methodology provides the resources and guidelines to 
assist in the development of surveillance programmes. (Hoffman, et al., 2015) 
1.2.2. The Global Antimicrobial Surveillance System (GLASS)  
 
Increasing globalisation has increased the ease with which infections, and thus resistance, can spread. 
This makes ABR in any one region of the world a global concern and the WHO has made much 
progress in developing means to address this problem. The primary goal of the GAP is to sustain the 
ability to treat infectious diseases with safe medicines. The following strategic objectives were 
outlined in order to achieve this goal: “(1) improve awareness and understanding of antimicrobial 
resistance through effective communication, education and training, (2) strengthen the knowledge and 
evidence base through surveillance and research , (3) reduce the incidence of infection through 
effective sanitation, hygiene and infection prevention measures, (4) optimize the use of antimicrobial 
medicines in human and animal health, (5) develop the economic case for sustainable investment that 
takes account of the needs of all countries, and increase investment in new medicines, diagnostic 
tools, vaccines and other interventions” (World Health Organisation, 2015 (a)). The GLASS 
programme aims to address the objective of obtaining standardised, comparable, validated data on 
ABR which can be shard on a global platform in order to guide prevention and control programmes 
(World Health Organisation, 2015 (b)). 
Differences in Antimicrobial Sensitivity Testing (AST) methods, variable quality control and 
differences in the choice of pathogens for surveillance are just a few of the shortfalls of existing 
surveillance data. Inadequate laboratory facilities to perform pathogen testing as well as limited 
human resourced has contributed to the lack of surveillance data in under resourced regions. The 
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GLASS early implementation phase between 2015 and 2019 aims to set up basic surveillance 
standards and provide baseline data on ABR on a global scale based on national reports submitted by 
participating member states. While environmental and animal data is also needed in order to address 
the problem of ABR holistically, for the initial phase the focus will be on human pathogens (World 
Health Organisation, 2015 (b)). 
The WHO has outlined priority pathogens based on specimen types, to be investigated in this phase of 
GLASS. Specific pathogen-drug combinations have been indicated in the GLASS manual, illustrated 
in Table 1. The rationale for selecting blood, urine, faeces and cervical/urethral swabs as sample types 
is that they represent the incidence of bloodstream infections, urinary tract infections, gastrointestinal 
infections and gonorrhoea respectively. The pathogens included for each specimen type are 
commonly encountered in both a community and hospital setting and represent infections that have 
important public health implications. These samples are easy processed and pathogen identification is 
straightforward (World Health Organisation, 2015 (b)). 
Table 1: Pathogen–antimicrobial combinations on which GLASS will gather data 
 
Pathogen Antibiotic Class Antibiotic  
Escherichia coli Sulfonamides and trimethoprim 
Fluoroquinolones 
Third-generation cephalosporins 
 
Fourth-generation cephalosporins 
Carbapenems 
 
Polymyxins 
Penicillins 
Cotrimoxazole 
Ciprofloxacin or levofloxacin 
Ceftriaxone or cefotaxime and 
ceftazidime 
Cefepime 
Imipenem, meropenem, ertapenem 
or doripenem 
Colistin 
Ampicillin 
Klebsiella pneumoniae Sulfonamides and trimethoprim 
Fluoroquinolones 
Third-generation cephalosporins 
 
Fourth-generation cephalosporins 
Carbapenems 
 
Polymyxins 
Cotrimoxazole 
Ciprofloxacin or levofloxacin 
Ceftriaxone or cefotaxime and 
ceftazidime 
Cefepime 
Imipenem, meropenem, ertapenem 
or doripenem 
Colistin 
A. baumannii Tetracyclines 
Aminoglycosides 
Carbapenems 
 
Polymyxins 
Tigecycline or minocycline 
Gentamicin and amikacin 
Imipenem, meropenem, ertapenem 
or doripenem 
Colistin 
S.  aureus Penicillinase-stable β-lactams Cefoxitin 
S. pneumoniae Penicillins 
 
Sulfonamides and trimethoprim 
Third-generation cephalosporins 
Oxacillin 
Penicillin G 
Cotrimoxazole 
Ceftriaxone or cefotaxime 
Salmonella spp. Fluoroquinolones 
Third-generation cephalosporins 
Carbapenem 
Ciprofloxacin or levofloxacin 
Ceftriaxone or cefotaxime and 
ceftazidime 
Imipenem, meropenem, ertapenem 
or doripenem 
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Shigella spp. Fluoroquinolones 
Third-generation cephalosporins 
Macrolides 
Ciprofloxacin or levofloxacin 
Ceftriaxone or cefotaxime and 
ceftazidime 
Azithromycin 
N. gonorrhoeae Third-generation cephalosporins 
Macrolides 
Aminocyclitols 
Fluoroquinolones 
Aminoglycosides 
Cefixime 
Ceftriaxone 
Azithromycin 
Spectinomycin 
Ciprofloxacin 
Gentamicin 
 
Patient data must be collected along with AST results and population data from the sample site. The 
surveillance data will be aggregated at a national level before reporting to the WHO annually (World 
Health Organisation, 2015 (b)). 
Existing resources can be used in the implementation of GLASS but to facilitate proper data 
collection where surveillance has not yet been established, the WHO has made the WHONET 
software available as a data capturing and analysis tool. This software includes the capacity for core 
patient data as well as AST results, the analysis of which can provide trends in the distribution of 
resistance as well as comparable data to view the change in resistance patterns over time (World 
Health Organisation, 2015 (b)).  
The implementation of GLASS will pave the way for the establishment of reliable surveillance 
systems. In the future, surveillance may be expanded to include other infections once the protocol and 
system for data collection and reporting has been established (World Health Organisation, 2015 (b)).  
In using the GLASS methodology, the following information can be obtained: 
 Population in which most AMR infections are presenting in terms of age and origin of 
infection (community or hospital) 
 The extent of resistance based on epidemiological and laboratory data 
 Changes in resistance patterns based on comparison of data year to year 
Using the outlined method of data collection and analysis we can obtain an overview of trends in 
resistance in KwaZulu Natal which can be compared to data available from other regions, nationally 
and globally and may be used as baseline data for further studies. 
These are also pathogens highlighted in the global priority pathogens list developed by the WHO in 
order to prioritise research and development into new antibiotics to treat antibiotic-resistant bacteria. 
Pathogens were grouped according to species and type of resistance and were classified as critical, 
high and medium priority. The following pathogens are classified as critical priority: carbapenem-
resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa and 
Enterobacteriaceae resistant to carbapenems and third generation cephalosporins. The following 
pathogens were classified as high priority: vancomycin-resistant Enterococcus faecium, 
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Staphylococcus aureus resistant to methicillin and vancomycin, clarithromycin-resistant Helicobacter 
pylori, fluoroquinolone-resistant Campylobacter, fluoroquinolone-resistant Salmonella spp. and 
Neisseria gonorrhoea resistant to fluoroquinolones and third generation cephalosporins. The 
following pathogens were classified as medium priority: penicillin-non-susceptible Streptococcus 
pneumoniae, ampicillin-resistant Haemophilus influenzae and fluoroquinolone-resistant Shigella spp. 
(World Health Organisation, 2017 (b)). 
1.2.3. Existing Surveillance Programs: 
 
Surveillance of ABR is essential in order to determine the extent of the problem and using that 
information, formulate measures to curb the incidence and spread of resistance. Surveillance 
programmes are carried out nationally in various countries as well as by independent organisations. In 
addition, many studies are carried out based on data from samples routinely sent to laboratories for 
clinical purposes. Existing surveillance programmes implement varying methodologies and cover 
different pathogens, antibiotics, specimen types and settings. Outlined below is an overview of 
various surveillance programmes and studies with a special focus on those that have included GLASS 
pathogens (World Health Organisation, 2014 (b)). 
1.2.3.1. WHO Programmes 
 
African Region 
The Integrated Disease Surveillance and Response (IDSR) system was adopted in the WHO Africa 
region in 1998, initially to monitor severe outbreaks of preventable infections. The project has since 
expanded to a regional surveillance network which aims to provide information on priority infections 
by strengthening surveillance programmes in member states and improving the use of surveillance 
data to guide clinical interventions. Measures include personnel training, integrating surveillance 
systems to promote efficient use of resources and improving the sharing of surveillance data. The 
contribution of data to the network is variable, depending on the resources and laboratory capacity in 
each participating country. The Gonococcal Antimicrobial Surveillance Programme (GASP) was 
initiated by the WHO in order to facilitate the collection of isolates in African countries by providing 
technical assistance and training (Centres for Disease Control and Prevention , 2015). 
The WHO instituted pilot programmes in Durban and Brits, South Africa, as part of a global pilot 
study in five cities in under-resourced countries.  In addition to the two South African sites, data was 
collected from three sites in India. The objective of the study was to investigate the feasibility and 
potential for ABR surveillance in resource limited settings by collecting prospective and retrospective 
drug usage data. The South African sites included E. coli isolates from urine samples and S. 
pneumoniae and H. influenzae isolates from sputum samples. These isolates were tested against 
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ampicillin, trimethoprim/sulfamethoxazole, cefalexin/cefuroxime, chloramphenicol and erythromycin. 
In terms of GLASS pathogens, at the Brits surveillance site, E. coli isolates were found to be 50 – 
65% resistant to ampicillin, trimethoprim/sulfamethoxazole and cefalexin/cefuroxime. At the Durban 
site, S. pneumoniae isolates showed the highest resistance to trimethoprim/ sulfamethoxazole (55%) 
followed by erythromycin (19%) and chloramphenicol (2%). The results highlighted the extensive use 
of antibiotics in both India and South Africa, with certain drugs more commonly used in community 
health centres in the public sector compared to the private sector and vice versa. In terms of the 
capacity for surveillance it was found that all sites were able to provide data, however methodological 
and logistic constraints were potential barriers to obtaining comparable data over long periods of time  
(Holloway, et al., 2011). These sites would be ideal for the implementation of GLASS methodology, 
which would enhance the quality and reliability of the data obtained and address some of the 
shortcomings of this study. 
 A review of the extent to which countries in the WHO African region have implemented the WHO 
Policy Package on AMR showed that none of the countries had robust, representative national 
surveillance programmes on antimicrobial use and resistance. Pilot projects in various countries 
include but are not limited to (1) a study implemented in Gambia investigating the prevalence of and 
risk factors for the faecal carriage of resistant Enterobacteriaceae by food handlers in schools; a study 
involving the characterisation and susceptibility of E.coli in street food and raw beef in Tamale, 
Ghana; sentinel surveillance in Togo of ESBL producing Enterobacteriaceae in children under the 
age of five hospitalised for acute gastroenteritis and the correlation of antibiotic drug use and 
resistance found in humans, food-producing animals and retail foods in Uganda. In Rwanda, Kenya, 
Burundi and Tanzania a study investigating the prevalence and characterisation of ESBL producing E. 
coli in animals, humans and the environment has also been implemented. While the results of most of 
the abovementioned studies are not yet available, they highlight the capacity and potential for 
surveillance in Africa and provide useful data in terms of ABR as well as in terms of identifying 
limitations of surveillance methods.  (Essack, et al., 2016). 
The 2014 WHO report on AMR noted the following resistance ranges from 2-13 countries of the 47 
member countries in the Africa Region): 
 E. coli to third generation cephalosporins: 2 – 70% (13 countries) 
 E. coli to fluoroquinolones: 14 – 71% (14 countries) 
 K. pneumoniae to third generation cephalosporins:  8 – 77%(13 countries) 
 K. pneumoniae to carbapenems: 0 – 4% (4 countries) 
 Incidence of methicillin-resistant Staphylococcus aureus (MRSA): 12 – 80% (9 countries) 
 S. pneumoniae to penicillin: 3 – 16% (5 countries) 
 Non-typhoidal Salmonella to fluoroquinolones: 0 – 35% (9 countries) 
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 Shigella spp. to fluoroquinolones: 0 – 3% (4 countries) 
 Decreased susceptibility to fluoroquinolones in N. gonorrhoea:  0 – 12% (2 countries) 
 (World Health Organisation (a), 2014). 
Region of the Americas 
Latin American Antimicrobial Resistance Surveillance Network (ReLAVRA) is a surveillance 
network focussing on Latin America and was implemented by the Pan American Health Organisation 
(PAHO) in conjunction with the WHO. The system was implemented in 1996 and involves 21 
countries, which submit surveillance data via National Reference Laboratories. There are four 
indicators pathogens, viz., E. coli, gonococci, Klebsiella spp and S. aureus. Based on the country-
specific data available on the PAHO website, several countries appear to contribute to the surveillance 
network but to different degrees. For example, in 2013 there was data from 15 countries for Klebsiella 
spp. but only from 7 countries for gonococci. The general trend observed between the year 2000 and 
2013 was an increase in ABR although the percentage of resistance fluctuated over the years as well 
as between countries. In 2013 resistance to third generation cephalosporins in Klebsiella spp. ranged 
from 19 – 84%, resistance to oxacillin, in hospital acquired S. aureus which indicates MRSA ranged 
from 34 – 78% and resistance to penicillin and ciprofloxacin in gonococci was more than 40% in most 
countries. Data on E. coli resistance was minimal, but data from Panama indicated that resistance to 
cefalotin, ciprofloxacin and trimethoprim/sulfamethoxazole ranged between 28 – 54% (World Health 
Organisation.(b), 2015) (Pan American Health Organisation, 2016). 
The 2014 WHO report on AMR reported the following resistance ranges from 4-17 countries of the 
35 member countries in the region of the Americas:  
 E. coli to third generation cephalosporins: 0 – 48% (14 countries) 
 E. coli to fluoroquinolones: 5 – 58% (16 countries) 
 K. pneumoniae to third generation cephalosporins: 4- 71% (17 countries) 
 K. pneumoniae to carbapenems: 0 – 11% (17 countries) 
 Incidence of MRSA: 21 – 90% (50 countries) 
 S. pneumoniae to penicillin: 0 – 48% (15 countries) 
 Non-typhoidal Salmonella to fluoroquinolones: 0 – 96% (13 countries) 
 Shigella spp. to fluoroquinolones: 0 – 8% (14 countries) 
 Decreased susceptibility to fluoroquinolones in N. gonorrhoea: 0 – 31% (4 countries) 
(World Health Organisation, 2014 (a)) 
Eastern Mediterranean Region 
Surveillance in this region so far has been largely disease-focussed and there is limited reliable data 
on the broader AMR situation. While the Eastern Mediterranean Regional Committee adopted 
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resolutions to address AMR, political and economic unrest in this region makes the co-ordination of 
broad surveillance studies difficult. (World Health Organisation, 2014) 
The 2014 WHO report on AMR reported the following resistance ranges from 2-5 countries of the 21 
member countries in the Eastern Mediterranean region:  
 E. coli to third generation cephalosporins: 22 – 63% (5 countries) 
 E. coli to fluoroquinolones: 21 – 62% (4 countries) 
 K. pneumoniae to third generation cephalosporins: 22 – 50% (4 countries) 
 K. pneumoniae to carbapenems: 0 – 54% (4 countries) 
 Incidence of MRSA: 10 – 53% (4 countries) 
 S. pneumoniae to penicillin: 13 -34% (3 countries) 
 Non-typhoidal Salmonella to fluoroquinolones: 2 – 49% (4 countries) 
 Shigella spp. to fluoroquinolones: 3- 10% (2 countries)  
 Decreased susceptibility to fluoroquinolones in N. gonorrhoea: 0 – 12% (2 countries 
(World Health Organisation, 2014 (a)) 
European Region 
Many countries within the European Union have established national surveillance programmes and all 
are participants in the European Antimicrobial Resistance Surveillance Network – EARS-Net. 
Countries outside of the European Union tend to have less well-established systems. The Central 
Asian and Eastern European Surveillance of Antimicrobial Resistance (CAESAR) is a WHO initiative 
involving countries who are not part of the European AMR Surveillance Network. The first report 
was published in 2014 from data submitted by five of the CAESAR participating countries while the 
remaining countries are in various stages of implementation of the surveillance program (World 
Health Organisation, 2014 (b)). 
AST results are obtained from blood and cerebrospinal fluid samples on eight bacterial pathogens of 
particular interest in terms of public health implications. These included E. coli, K. pneumoniae, 
Pseudomonas aeruginosa, Acinetobacter spp., S. aureus, S. pneumoniae, Enterococcus faecalis and 
Enterococcus faecium. Data includes AST information on selected antimicrobial groups and 
resistance patterns reported as country-specific data. The data for each country is given a level of 
reliability based on the extent to which the data was representative of the entire population (World 
Health Organisation, 2014 (b)). 
.  
The WHO 2014 report on surveillance reported the following resistance ranges from 10-36 countries 
of the 53 member countries in the European Region:  
 E. coli to third generation cephalosporins: 3 – 82% (35 countries) 
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 E. coli to fluoroquinolones: 8 – 48% (35 countries) 
 K. pneumoniae to third generation cephalosporins: 2 – 82% (33 countries) 
 K. pneumoniae to carbapenems: 0 -68% (31 countries) 
 Incidence of MRSA: 0.3 – 60% (36 countries) 
 S. pneumoniae to penicillin: 0 – 61% (31 countries) 
 Non-typhoidal Salmonella to fluoroquinolones: 2 – 3% (29 countries) 
 Shigella spp. to fluoroquinolones: 0 – 47% (10 countries) 
 Decreased susceptibility to fluoroquinolones in N. gonorrhoea: 0 – 36% (17 countries)  
(World Health Organisation, 2014 (a)) 
South-East Asia Region 
AMR data in this part of the world appears to be limited aside from a few countries such as Thailand 
and India. In the Regional Strategy on Prevention and Containment of Antimicrobial Resistance 
published by the WHO in 2010 it was reported that no systematic prospective AMR studies had been 
conducted in the region database (World Health Organisation, 2010 (a)). In August 2012 “A Roadmap 
to Tackle the Challenge of Antimicrobial Resistance – A Joint meeting of Medical Societies in India” 
was conducted with the purpose of developing a plan for combatting ABR in Chennai, India. The 
Chennai Declaration, made by all delegates at the meeting, highlighted the roles of individuals in 
encouraging rational drug use, ABR surveillance, AST to guide treatment and improving infection 
control. The WHO was urged to provide technical and financial support in resource limited settings 
and most importantly co-ordinate initiatives on a global scale. In 2013 all 11 Member States of the 
region signed the Jaipur Declaration on AMR and agreed to contribute data towards a regional 
(Ghafur, et al., 2013).  
The WHO regional strategy for the period 2010-2015 aimed to increase awareness about AMR, 
encourage the rational use of antibiotics as well as to institute surveillance systems with inter-regional 
collaboration. A subsequent report on a meeting of 20 member states of the SEA region indicated that 
the available resistance data was mainly on HIV, tuberculosis, measles and diarrhoeal diseases. Data 
also commonly included extended spectrum β-lactamase (ESBL) producing bacteria, MRSA and N. 
gonorrhoea as well as specific antibiotics such as penicillin and ciprofloxacin. The general trend was 
an increase in resistance with specific concern regarding the increasing resistance to cephalosporins 
and carbapenems (World Health Organisation, 2013). 
 Various organisations have conducted AMR surveillance in the SEA region including independent 
laboratories, academic institutions and NGO’s. The Sri Lanka College of Microbiologists conducted 
surveillance on AMR in Gram-negative organisms from several surveillance sites and planned to 
expand the program to include Gram-positive organisms as well as more surveillance sites. In the 
Maldives the Indira Gandhi Memorial Hospital (IGMH) Laboratory information system was able to 
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provide limited resistance data showing the increasing patterns of resistance in the country. Other 
countries which reported some form of AMR data analysis included Nepal, Timor-Leste, Bangladesh, 
and Indonesia. (World Health Organisation, 2013) The surveillance data available in the SEA region 
was often as a result of activity by groups such as the International Network on Rational Use of Drugs 
(INRUD), ReAct- Action on Antibiotic Resistance, International Network for the Demographic 
Evaluation of Populations and Their Health in Under-Resourced Countries (INDEPTH), Alliance for 
Prudent Use of Antibiotics (APUA), Health Action International (Asia Pacific) (HAIAP) and the 
Global Antibiotic Resistance Partnership (GARP). Since the call for action on AMR was made, 
countries within the region are reported to have adopted national action plans and have made progress 
in implementing AST, awareness and surveillance projects. (World Health Organisation South-East 
Asia, 2010) 
The WHO 2014 report on surveillance reported the following resistance ranges from 2-5 countries of 
the 11 member countries in South-East Asia region: 
 E. coli to third generation cephalosporins: 16 – 68% (5 countries) 
 E. coli to fluoroquinolones: 32 – 64% (5 countries) 
 K. pneumoniae to third generation cephalosporins: 34 – 81% (4 countries) 
 K. pneumoniae to carbapenems: 0 – 8% (4 countries) 
 Incidence of MRSA: 10 – 26% (3 countries) 
 S. pneumoniae to penicillin: 47 – 48% (2 countries) 
 Non-typhoidal Salmonella to fluoroquinolones: 0.2 – 4% (2 countries) 
 Decreased susceptibility to fluoroquinolones in N. gonorrhoea: 0 – 5% (5 countries)  
(World Health Organisation, 2014 (a)) 
Western Pacific Region 
In the 1980s, 14 Member States in this region agreed to collect AMR data on key pathogens, however 
this was disrupted due to other emergencies and co-ordination of AMR efforts between states was 
diminished although some countries continued surveillance on a national level. More recently, efforts 
have been made to re-establish AMR surveillance at a regional level (World Health Organisation (a), 
2014). 
The WHO 2014 report on surveillance reported the following resistance ranges from 4-16 countries of 
the 27 member countries in the Western Pacific region: 
 E. coli resistance to third generation cephalosporins: 0 – 77% (13 countries) 
 E. coli resistance to fluoroquinolones: 3 – 96% (16 countries) 
 K. pneumoniae to third generation cephalosporins: 1 – 72% (14 countries) 
 K. pneumoniae to carbapenems: 0 – 8% (9 countries) 
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 Incidence of MRSA: 4 – 84% (16 countries) 
 S. pneumoniae to penicillin: 0 – 47% (10 countries) 
 Non-typhoidal Salmonella to fluoroquinolones: 0 – 14% (9 countries) 
 Shigella spp. to fluoroquinolones: 3 – 28% (4 countries) 
 Decreased susceptibility to fluoroquinolones in N. gonorrhoea: 0 – 31% (12 countries)  
(World Health Organisation, 2014 (a)) 
1.2.3.2. Global and Regional Surveillance Programmes 
The Alexander Project and the Survey of Antibiotic Resistance (SOAR) 
Initiated in 1992 by GlaxoSmithKline, the Alexander Project gathered data until 2001 and included 
three prominent respiratory pathogens: H. influenza, Moraxella catarrhalis and S. pneumoniae. 
Isolates from adult patients with community-acquired respiratory tract infections were obtained from 
surveillance sites in the USA, Mexico, Brazil, South Africa, Saudi Arabia, Hong Kong and European 
countries making it the first of its kind to compare standardised, quality data on an international level. 
MICs were established for a panel of 15 antibiotics including β-lactams, macrolides, fluoroquinolones 
and trimethoprim/sulfamethoxazole. Trends in resistance for each pathogen within and across the 
different classes of antibiotics were established, with the MIC values providing key information for 
many papers published based on the project. (Felmingham, et al., 2005) 
Between 1992 and 2001 there was an increase in multi-drug resistant infections with differences in 
resistance patterns between regions. Of specific interest is the data on S. pneumoniae, a GLASS 
pathogen, which showed high levels of penicillin-erythromycin co-resistance but a low prevalence of 
fluoroquinolone resistance in Europe and the USA. (Felmingham, et al., 2005). 
 After the Alexander Project was concluded in 2001, GlaxoSmithKline initiated the Survey of 
Antibiotic Resistance Study (SOAR) in 2002 which also tracks ABR in respiratory infections. The 
latest findings for the SOAR project were published in 2016 and data for the next cycle of 
publications is being collated. Results from the African countries, including the Democratic Republic 
of Congo, Ivory Coast, Republic of Senegal and Kenya, showed that resistance to penicillin and 
trimethoprim/sulfamethoxazole in S. pneumoniae ranged from 0 – 35% and 21 – 57% respectively. 
Although other antibiotics were included in the panel, penicillin and trimethoprim/sulfamethoxazole 
are reported here as part of the GLASS panel of antibiotics for S. pneumoniae (Kacou-Ndouba et al., 
2016) 
SENTRY 
The SENTRY Antimicrobial Programme is an ongoing initiative that was started in 1997 and is 
funded by various pharmaceutical companies. Data on both nosocomial and community acquired 
infections are submitted by sentinel hospitals in the Americas, Europe and the Asia-Pacific region. 
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The project includes the collection of surveillance data relating both to susceptibility data as well as 
investigation into resistance mechanisms. Reports on the data have been used as an indicator of the 
status of ABR in various regions of the world including South Africa (Masterton, 2008). Results cited 
in various studies will be discussed in more detail in the sections below. 
 Five major objectives of the programme were to monitor bacteraemia, outpatient respiratory tract 
infections, pneumonia in hospitalised patients, wound infections and urinary tract infections. The 
inclusion of these infections provided good insight into common infectious diseases which are of 
significance in terms of public health and the corresponding demographic and epidemiological data 
allowed for extensive comparison of resistance trends in each geographical region (Masterton, 2008). 
A wide range of gram-positive and gram-negative bacteria have been investigated and numerous 
articles based on SENTRY data highlight trends in terms of specific pathogens, types of infections 
and antimicrobial agents. Of the GLASS pathogens, S. aureus, A. baumannii, S. pneumoniae and E. 
coli have been extensively monitored and the data shows that S. aureus was the most common 
causative pathogen of blood stream infections, pneumonia and soft tissue infections in almost all 
participating regions. The emergence of multi-drug resistant infections was clear, as was the 
distribution of resistance and variations in susceptibility patterns of pathogens across geographical 
regions. Between 1997 and 1999, susceptibility of S. pneumoniae isolates to penicillin and 
cefpodoxime varied from 6.8% and 9.2% in Canada to 17.8% and 22.9% in the Asia-Pacific region 
(Hoban, et al., 2001). A study conducted by Diekema et al., (2001) reported that isolates obtained 
from sites in Canada and the USA were generally more susceptible to all recorded drugs but that the 
nosocomial isolates showed higher resistance rates to β-lactam antibiotics than community acquired 
isolates. This was in contrast to Latin America where higher rates of resistance were reported with no 
major difference in β-lactam susceptibility between nosocomial and community acquired isolates.  
(Diekema, et al., 2001) 
Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program 
The MYSTIC programme was started in 1997 and focussed on the susceptibility of nosocomial 
infections to meropenem and other antibiotic agents by measuring MIC values. The study focussed on 
the Americas, Europe and the Middle East and the data was used together with antibiotic 
pharmacokinetic/pharmacodynamics data in the Optimizing Pharmacodynamic Target Attainment 
using the MYSTIC Antibiogram (OPTAMA) Program to provide insight into the optimal dosage to 
prevent the development of resistance. In addition, meropenem usage data was also collected in order 
to correlate usage and resistance patterns. Both Gram-positive and Gram-negative bacterial isolates 
were tested including S. aureus, P. aeruginosa, A. baumannii, Enterobacteriaceae and many others. 
Over the years the results of studies based on MYSTIC data have shown that meropenem is one of the 
more active broad-spectrum antibiotics but resistance to carbapenems is on the increase (Turner, 
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2000). A study published in 2008 looking at 11 years of data from a paediatric ICU found that a 
number of MDR isolates were susceptible to meropenem but resistant to all other agents. The study 
also found that the consumption of cephalosporins decreased over the study period, however the use 
of carbapenems increased significantly, which can be correlated with the increasing incidence of 
carbapenem resistance that has emerged in recent years (Patzer, et al., 2008). 
European Antimicrobial Resistance Surveillance Network (EARS-Net) 
The European Antimicrobial Resistance Surveillance Network (EARS-Net) includes 30 countries and 
is a continuation of the European Antimicrobial Resistance Surveillance System (EARSS). 
Participating countries provide reports on the pathogens and antimicrobial agents under surveillance 
and have contributed towards a growing network of increasingly comparable AMR data. 
Representatives from Member States collate the AMR susceptibility data with regard to isolates from 
cerebrospinal fluid and blood samples from national surveillance sites. (European Centre for Disease 
Prevention and Control, 2015) 
The standard of surveillance in the EU Member States was streamlined by the introduction of the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST), which provides guidelines 
on susceptibility testing. This has allowed for greater uniformity and thus more comparable data to be 
collected from EARS-Net Member States. (European Centre for Disease Prevention and Control, 
2015) (European Committee on Antimicrobial Susceptibility Testing, 2016) 
The 2016 annual report included the AMR data for 2016 as well as a trend analysis of resistance in the 
region based on data from 2013 to 2016.  Varying resistance patterns were noted throughout Europe 
between 2013 and 2016, but a general increase in resistance in E. coli to third generation 
cephalosporins and aminoglycosides was observed while resistance in K. pneumoniae appeared to 
stabilise with several countries reporting a decrease in resistance in K. pneumoniae to most antibiotic 
groups. For E. coli in 2016, over 50% of isolates were resistant to at least one antibiotic with the 
highest resistance reported to aminopenicillins (57%) while resistance to carbapenems remained low 
(< 0.1%). Resistance in E. coli to third generation cephalosporins remained stable at 12 - 13% while 
resistance to fluoroquinolones decreased from 22.5% to 21% over the 4 years. In K. pneumoniae 
resistance to fluoroquinolones decreased from 29.3% to 24.6%, resistance to third generation 
cephalosporins decreased from 30.1% to 25.7% and resistance to carbapenems decreased from 8.2% 
to 6.1%. Carbapenem resistance was found to be more common in Acinetobacter spp. isolates with an 
average of 35% resistance reported in 2016 with at least 6 countries reporting resistance greater than 
70%. In S. pneumoniae isolates, resistance varied greatly between countries with non-susceptibility to 
penicillin ranging from 0.4% to 41.1% in 2016. Resistance to macrolides was 0 – 60% but in most 
countries, was higher than non-susceptibility to penicillins. The incidence of MRSA varied between 
countries, ranging between 1.2% and 50.5% in 2016, while the average incidence of MRSA in the 
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region decreased from 18.1% in 2013 to 13.7% in 2016 (European Centre for Disease Prevention and 
Control, 2017)  (European Centre for Disease Prevention and Control, 2015). 
In addition to EARS-Net which it administrates, the European Centre for Disease Control (ECDC) 
also funded the European Survey on Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) 
which collected data between 2013 and 2014 and highlighted the increase in carbapenem resistance in 
K. pneumoniae as a cause for concern. Out of all the carbapenemase-producing isolates identified, the 
ratio between K. pneumoniae and E. coli was 11:1 (Grundmann et al., 2017). 
1.2.3.3. National Surveillance Programmes 
English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) 
In 2013, the United Kingdom published a strategy on AMR surveillance and ESPAUR was 
subsequently started as part of the strategy. ESPAUR collaborates with the ECDC and EARS-Net in 
order to enhance surveillance methods and contribute towards the broader AMR information network. 
Data from routine susceptibility testing is entered into a national database from hospitals across 
England and results are reported as pathogen-drug combinations (England Surveillance Programme 
for Antimicrobial Use and Resistance (ESPAUR), 2015). 
Due to the increasing incidence of carbapenem resistance, an Electronic Reporting System (ERS) was 
implemented in 2015 for the enhanced surveillance of carbapenemase-producing Gram-negative 
bacteria. Between May 2015 and May 2017 there were 3 166 confirmed carbapenemase-producing 
organisms reported out of the 6 208 organisms submitted for testing. Sixty four percent of 
carbapenemase-producing Enterobacteriaceae (CPE) were isolated from rectal or faecal specimens 
(England Surveillance Programme for Antimicrobial Use and Resistance (ESPAUR), 2017). 
The ESPAUR 2017 report, which included data between 2012 and 2016, highlighted the trends in 
resistance with respect to the different types of infection as well as by pathogen with specific focus on 
E. coli, K. pneumoniae and P. aeruginosa. In terms of results relevant to the GLASS methodology, 
bacteraemia caused by E. coli and K. pneumoniae, UTIs caused by E. coli and resistance in N. 
gonorrhoea was reported on. The proportion of non-susceptible E. coli isolates from blood samples 
remained stable between 2012 and 2016 although the incidence of bacteraemia caused by E. coli 
increased by 24.3% during this period with 40 272 cases reported in 2016. Isolates showed the highest 
resistance to amoxicillin/clavulanate (37.3% - 40.8%) followed by ciprofloxacin (18.1% - 18.7%) and 
third generation cephalosporins (10.8% - 12.4%) while carbapenem resistance remained low (0.07% - 
0.14%). A similar trend of stable proportions of resistant isolates between 2012 and 2016 was 
observed in bloodstream infections caused by K. pneumoniae with resistance to ciprofloxacin and 
third generation cephalosporins fluctuating within the range of 10.0 – 12.3%. Carbapenem resistance 
was slightly higher than in E. coli isolates ranging from 0.8% to 1.15% (ESPAUR, 2017). 
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It was found that the underlying cause of approximately 50% of cases of bacteraemia was a UTI.  
Isolates were included from the community setting as well as the acute hospital setting. The majority 
of isolates (97%) were susceptible to first-line treatment nitrofurantoin but 34-37% of isolates were 
found to be resistant to trimethoprim, which is recommended where there is a low risk of resistance. 
Resistance to ciprofloxacin, the recommended treatment for complicated UTIs and pyelonephritis, 
was found to be 12% to 15% (ESPAUR, 2017). 
 The data regarding N. gonorrhoea showed that resistance to the first line drugs ceftriaxone and 
azithromycin was low. No isolates were found to be resistant to ceftriaxone and resistance to 
azithromycin showed a slight decline from 9.8% in 2015 to 4.7% in 2016 (ESPAUR, 2017). 
India 
Antimicrobial susceptibility testing is conducted by a number of public and private laboratories in 
India, however systematic surveillance is limited. A surveillance study supported by the WHO was 
carried out in Mumbai, New Delhi and Vellore between 2002 and 2005 looking at resistance in E. 
coli. There was high resistance to ampicillin (46 – 50%) and trimethoprim/sulfamethoxazole (45 – 
65%)  (Global Antibiotic Resistance Partnership-India National Working Group, 2011). Initiatives 
which have been active in India include the Indian Clinical Epidemiology Network (IndiaClen) which 
implemented the Invasive Bacterial Infection Surveillance (IBIS) project, the Indian Initiative for 
Management of Antibiotic Resistance (IIMAR) and the Indian Network for Surveillance of 
Antimicrobial Resistance (INSAR). These initiatives have spanned both the public and private sector 
and have included various pathogens (World Health Organisation South-East Asia, 2010). 
 
Diarrhoeal and respiratory infections are responsible for 8% and 6% of deaths in India respectively 
and the associated resistance of the causative pathogens to antibiotics make the surveillance of 
antibiotic use and resistance a necessity in trying to improve public health outcomes. Studies have 
been carried out at various health facilities with the focus on hospital acquired infections (HAIs) by 
ward type as well as pathogen specific studies (Global Antibiotic Resistance Partnership-India 
National Working Group, 2011). 
In the GARP India situational analysis published in 2011, S. aureus and P. aeruginosa were reported 
to be the most common causative pathogens in terms of HAIs and resistance data showed multi-drug 
resistance as high as 96% in a study including burn patients. P. aeruginosa isolates showed especially 
high resistance to tobramycin (83.6%) and amikacin (55.1%). The incidence of MRSA throughout 
India from past and present surveillance studies ranged from zero to almost 100%. A study carried out 
in Vellore between 1993 and 1994 found that 24% of S. aureus isolates were methicillin resistant and 
that resistance was >75% to gentamicin, ciprofloxacin and trimethoprim/sulfamethoxazole. Of the 
other GLASS pathogens, studies involving A. baumannii showed >80% resistance to third generation 
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cephalosporins with the presence of ESBLs but a relatively smaller percentage of organisms were 
resistant to carbapenems (8%). High levels of third generation cephalosporin resistance was also 
found in a study on K. pneumoniae from urine samples (68%). Results of several studies showed that 
up to 60% of E. coli isolates obtained from various surveillance sites were resistant to at least one 
antibiotic. A study conducted in New Delhi found that 67% of S. typhi isolates from children admitted 
to hospital with typhoid fever were multidrug resistant. Resistance among Salmonella species was 
found to be high (>70%) against ampicillin, ciprofloxacin and chloramphenicol but relatively lower 
against gentamicin (>90%). The data available regarding the susceptibility of N. gonorrhoea was of 
concern as a study conducted in a community setting between 2002 and 2003 found 78% of the 
isolates resistant to ciprofloxacin, 51% to tetracycline and 47% to penicillin (Global Antibiotic 
Resistance Partnership-India National Working Group, 2011). 
Thailand 
In Thailand surveillance of AMR has been implemented on a national level with respect to both 
human and animal health. The National Antimicrobial Resistance Surveillance in Thailand (NARST) 
was started in 1997 and has since expanded to include more surveillance sites. Surveillance data 
available from the NARST web page indicated a general trend of increasing resistance. Enterococcus 
spp. showed 84.1% and 69.7% resistance to tetracycline and erythromycin respectively in 2015 while 
vancomycin and teicoplanin showed the greatest sensitivity with only 3% of isolates showing 
resistance. Thirty-nine percent of S. pneumoniae were found to be resistant to erythromycin in 2016 as 
opposed to 48% in 2009, with >30% isolates resistant to erythromycin and/or clindamycin. Resistance 
of S. aureus isolates to erythromycin, clindamycin, ciprofloxacin and cefoxitin was found to be high 
(26 – 36%) in 2016 with resistance to cefoxitin being the highest (36.8%). Resistance to ampicillin 
was found to be especially high in E. coli and K. pneumoniae isolates which showed 86% and 99% 
resistance in 2016 respectively. There was a sharp drop in resistance to ampicillin/sulbactam in non-
typhoidal Salmonella isolated from blood, dropping from 80% in 2002 to 7% in 2016, however 
resistance to ampicillin remained high in 2016 at 66%. Of special concern was the trend in resistance 
of A. baumannii isolates to multiple antibiotic agents. In 2016 greater than 50% resistance was found 
to amikacin, cefepime, ciprofloxacin, piperacillin/tazobactam, ampicillin/sulbactam and imipenem 
(National Antimicrobial Resistance Surveillance Centre, Thailand, 2015). 
 An Invasive Bacterial Infection Surveillance (Thai-IBIS) was also established in 2005. The United 
States Centres for Disease Control (CDC) works closely with the Thailand Ministry of Public Health 
to improve the prevention strategies for infectious diseases  (World Health Organisation South-East 
Asia, 2010). The CDC is also active in the rest of the Southeast Asia region and has established the 
Immigrant, Refugee, and Migrant Health Program (IRMHP). There are several awareness 
programmes aimed at encouraging the rational use of antibiotics through educational courses as well 
as through an initiative by the Thai Food and Drug Administration (FDA) “Antibiotics Smart Use – 
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ASU” Project supported by the WHO, however awareness within the general community is still 
limited (U.S. Centers for Disease Control and Prevention, 2009). 
National Surveillance and Reporting of Antimicrobial Resistance and Antibiotic Usage for Human 
Health in Australia 
While Australia has a wealth of laboratories which provide antimicrobial susceptibility testing, a 
report published in 2013 stated that there was limited aggregation or analysis of the data at a national 
level and little standardisation and co-ordination occurred between surveillance sites. The Australian 
Group on Antimicrobial Resistance (AGAR), the National Neisseria Network (NNN) and the National 
Antimicrobial Utilisation Surveillance Program (NAUSP) are examples of surveillance programmes 
in Australia which have collected susceptibility data on several pathogens in the hospital and 
community setting, most commonly covering Enterobacteriaceae and S. aureus. Data from the S.  
aureus 2011 Antimicrobial Susceptibility Report noted MRSA in 29 – 36% of isolates, while the data 
from the Gram-negative Bacteria 2011 Hospital-onset Susceptibility Report evidenced high levels of 
resistance in E. coli to ampicillin (50.5%) while resistance in K. pneumoniae was highest to cefazolin 
(18%) and trimethoprim (18%) (Shaban, et al., 2013). Resistance in N. gonorrhoea isolates to 
fluoroquinolones in 2000 was reported to be 10%  (Tapsall, et al., 2008). Based on existing 
surveillance networks such as EARS-Net, the Australian government outlined a national action plan 
with clear objectives to collect comparable and validated AMR (AMR) data (Shaban, et al., 2013). 
National Antimicrobial Resistance Monitoring System- Enteric Bacteria (NARMS) 
The NARMS programme was started in the USA by the Centres for Disease Control (CDC), the Food 
and Drug Administration (FDA) and the US Department of Agriculture. NARMS collects data 
regarding enteric bacteria including Salmonella, Campylobacter, Shigella, E. coli from humans, retail 
meat and food animal sources. NARMS investigates emerging resistance trends in order to guide 
health policies, inform consumers about food-borne diseases and encourage rational use of antibiotics. 
The CDC oversees a number of other surveillance programmes including the Gonococcal Isolate 
Surveillance Project (GISP) and the Healthcare-Associated Infections-Community Interface. The 
NARMS 2014 Human Data Report showed that resistance to ciprofloxacin in non-typhoidal 
Salmonella and Shigella spp. was 0.4% and 2.4% respectively and resistance in E. coli was highest to 
tetracycline and sulfisoxazole (7%)  (Centres for Disease Control, 2016). The CDC also released a 
report in 2013 tracking the status of resistance in all pathogens of public health concern. The data 
showed that carbapenem resistance especially in K. pneumoniae (2%) and E. coli (11%) was of urgent 
concern as it translated to increasing difficulty in treating carbapenem-resistant Enterobacteriaceae 
(CRE) infections. MDR gonorrhoea was also highlighted as a serious concern with 30% resistance to 
cephalosporins, tetracycline and azithromycin in N. gonorrhoea. Other pathogens which were 
highlighted were MDR Acinetobacter, ESBL producing Enterobacteriaceae, drug resistant Shigella 
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spp, Salmonella spp, S. pneumoniae, P. aeruginosa and MRSA (Centres for Disease Control and 
Prevention, 2014). 
1.2.4. ABR and ABR Surveillance in South Africa: 
South Africa has a national AMR strategy framework, which is supported by antibiotic stewardship, 
increased surveillance and measures to prevent the spread of infection through vaccination and 
infection prevention and control. The framework also aims to take a comprehensive approach in 
dealing with AMR by implementing regulatory measures to improve the use of medicines through the 
Medicines Control Council (MCC) and the National Drug Policy (NDP). The national framework also 
highlights the need for co-operation from health professionals, members of the agricultural 
community as well as professionals in the veterinary field (Mendelson & Matsotso, 2015). 
 The surveillance indicated in the framework is specifically aimed at resistance data, drug 
consumption trends, drug quality as well as the occurrence of medication errors. Through the 
education measures suggested, the stage has already been set for the implementation of antibiotic 
surveillance according to WHO surveillance standards. Through the guidelines set forth in the 
GLASS early implementation manual, the existing AMR strategy framework can be optimised in 
order to provide data that is useful on both a national and international scale (Mendelson & Matsotso, 
2015). 
As the two infectious diseases which cause the highest numbers of deaths in South Africa, HIV and 
TB have been the focus of numerous studies. The National Institute for Communicable Diseases 
(NICD) undertakes surveillance on diarrhoeal diseases, which have a direct impact on infant mortality 
as well as epidemic-prone infections such as cholera, typhoid fever and meningococcal disease. An 
analysis of AMR in South Africa carried out in 2011 by the Global Antibiotic Resistance Partnership–
South Africa (GARP–SA) found that there was an urgent need for action in establishing standardised 
surveillance methods. There are limitations in population representation in existing data which stems 
mainly from central academic sites.  Existing surveillance data thus does not represent the status of 
AMR in the entire population. The Centre for Healthcare Associated Infections, Antimicrobial 
Resistance and Mycoses, a branch of the NICD, conducts laboratory based antimicrobial resistance 
surveillance (LARS) since 2010 and collects data from sentinel sites.  Electronic surveillance was 
implemented in 2013 and collects data from laboratory information systems in order to generate 
resistance maps. Enhanced surveillance has been implemented for methicillin-resistant S. aureus 
(MRSA) in order to determine the prevalence and extent of nosocomial and community-acquired 
MRSA infections. Enhanced surveillance is also underway for carbapenem-resistant 
Enterobacteriaceae (CREs)  (Mendelson & Matsotso, 2015). 
Existing surveillance data in South Africa which include pathogens of interest recommend by GLASS 
will be discussed below per infection type. 
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Blood Stream Infections 
Enhanced surveillance of S. aureus bacteraemia (SAB) was conducted in 3 public sector hospitals in 
Gauteng, South Africa between 2012 and 2013. Core patient data, treatment information as well as 
antimicrobial susceptibility data were included in the study which provided a comprehensive and 
detailed picture of the incidence of SAB in the hospitals involved. AST results showed that 36% of 
the isolates were MRSA and that longer hospital stays, HIV infection, frequent hospitalisation and 
recent antibiotic use were predictors of MRSA infection (Fortuin-de Smit, et al., 2015). A wider study 
was conducted between 2010 and 2012 including thirteen academic hospitals around South Africa 
which looked at AMR trends and molecular epidemiology of SAB.  S. aureus isolates were obtained 
from blood cultures over two years from academic hospitals in the public sector. There was a greater 
incidence of MRSA in Gauteng than in the other three provinces represented in the study and a variety 
of MRSA clones were present in South Africa. Methicillin resistance was found in 46% of isolates, 
but the incidence of MRSA decreased from 53% in 2010 to 40% in 2012 (Perovic, et al., 2015). The 
GLASS methodology recommends cefoxitin to be included in the panel for S. aureus as it is an 
indicator for methicillin resistance (World Health Organisation (b), 2015). 
 
 A national surveillance study was carried out in 2014 based on data obtained from public laboratories 
conducting AST for various hospitals in different provinces. Results from laboratory data using the 
Vitek and disk diffusion tests were analysed according to Clinical Laboratory Standards Institute 
(CLSI) guidelines. The study focussed on bloodstream infections caused by eight pathogens and the 
susceptibility profiles obtained were analysed. A. baumannii isolates showed the greatest resistance to 
piperacillin/tazobactam with more than 80% resistance, while susceptibility to colistin was retained at 
almost 100% followed by amikacin and levofloxacin which evidenced approximately 60% 
susceptibility. The other antibiotics including cephalosporins and carbapenems amongst others, 
showed resistance ranging between 70% and 80%. S. aureus isolates showed almost 0% susceptibility 
to penicillin, however the susceptibility to all other agents was found to be greater than 50%. The 
presence of ESBL producing pathogens including E. coli and K. pneumoniae was also detected, but 
both pathogens were almost 100% sensitive to carbapenems and amikacin (Perovic, et al., 2014). 
The 2015 annual report of the Group for Enteric Respiratory and Meningeal Disease Surveillance in 
South Africa (GERMS-SA) published by the NICD reported national surveillance data from 36 
enhanced surveillance hospital sites. Diseases under surveillance included opportunistic, nosocomial, 
epidemic-prone and vaccine-preventable infections throughout the 9 provinces. The GERMS-SA 
surveillance project includes susceptibility results from over 200 laboratories and covers a population 
of approximately 54.9 million. Methods such as the electronic capture on mobile phones of enhanced 
surveillance case report forms by surveillance officers has improved the ease of data capture and 
21 
surveillance site audits ensure that quality control is maintained (GERMS-SA, 2013) (GERMS-SA, 
2015). 
 
The GERMS-SA 2015 report included data on invasive pneumococcal disease, which in addition to 
blood samples, included isolates from the cerebro-spinal fluid (CSF) and other sources.  The 
resistance data showed low levels of penicillin resistance (4%) in S. pneumoniae.  Isolates have shown 
high levels of penicillin resistance in some studies, while significantly lower levels in others, leaving 
the overall level of penicillin resistance in the country at intermediate (GERMS-SA, 2015). Resistance 
to other classes of antibiotics has also been reported. Data from Johannesburg obtained as part of the 
Alexander Project in 1999 reported 79% of isolates to be penicillin-resistant and other data from the 
same year reported MDR in 37% of isolates  (Crowther-Gibson, et al., 2011). The GERMS-SA 2015 
report found MRSA in 33% of isolates, an increase from 29% reported in 2013 and resistance to 
clindamycin was 29% (GERMS-SA, 2015) (GERMS-SA, 2013). 
 
Diarrhoeal Infections 
The GERMS-SA 2015 report found that Salmonella typhi isolates showed a slight increase in 
resistance to ciprofloxacin, the first line treatment for diarrhoeal infections, from 10% in 2013 to 14% 
in 2015. No resistance was reported to azithromycin which could be used as alternative treatment 
options in cases of treatment failure with ciprofloxacin. In non-typhoidal Salmonella isolates 
resistance to ciprofloxacin was 21% while resistance to azithromycin was reported to be 1%. Shigella 
isolates showed low resistance (1%) to ciprofloxacin and azithromycin, although this is greater than 
the 0.1% resistance to ciprofloxacin reported in 2013 (GERMS-SA, 2015). 
 
The GARP-SA situation analysis on ABR published in 2011 reported a decline in resistance to 
ampicillin in Salmonella typhi from 40% in 2006 to 10% in 2010. Resistance declined in non-
typhoidal Salmonella isolates as well from 64% to 16% between 2003 and 2010. Resistance to 
ciprofloxacin was <1% in non-typhoidal Salmonella and S. typhi isolates in 2010. In Shigella spp., 
high resistance rates to older antibiotics such as ampicillin, tetracycline and sulfamethoxazole was 
reported (≥50%), including a high prevalence of MDR isolates, while resistance to the current first-
line treatment, naladixic acid, remained low (1%) (Gelband & Duse, 2011). 
Urinary Tract Infections 
A study conducted in Gauteng by Lewis et.al in 2013 investigated the aetiology of UTI’s in women 
from public and private healthcare facilities and included antibiotic prescribing data. Gram-negative 
bacteria, including E. coli and K. pneumoniae, were the most common causative pathogens. 
Resistance in Gram-negative bacilli was higher for trimethoprim/sulfamethoxazole (59%) and 
22 
amoxicillin-clavulanate (19%) than ciprofloxacin (6%). Susceptibility to cephalosporins was greater 
than 90% (Lewis et.al. 2013 (a)).  
 
Another study was carried out between 2010 and 2012 with K. pneumoniae as the sentinel organism 
in 13 public sector healthcare sites in Gauteng, KwaZulu Natal, Limpopo, Free State and Western 
Cape provinces. Resistance to third generation cephalosporins was found to be greater than 70% while 
susceptibility to carbapenems and colistin was greater than 85% in 2012 (Perovic, et al., 2014).  
Coetzee et al. reported in 2016 that increasing colistin resistance in E. coli isolates was becoming a 
serious concern and that the use of colistin as a last resort was becoming more common due to 
resistance to other antibiotics. Resistance was thought to be spread by the presence of the mcr-1 gene 
in food animals such as pork and poultry, the presence of which has been confirmed by surveillance 
of poultry operations in South Africa. The mcr-1 gene has also been detected in colistin-resistant E. 
coli in hospitalised and outpatient-based patients in South Africa (Coetzee et al., 2016). 
Such studies show that there is the capacity for the collection of usable, detailed data as required for 
GLASS as E. coli and K. pneumoniae are the pathogens of interest for urine samples. These existing 
findings are useful as a means of comparing the results of this study to the existing knowledge base. 
Gonorrhoea  
Gonorrhoea is the only STI to be investigated in terms of ABR in South Africa.  Isolates were found 
to be susceptible to ciprofloxacin until 2003, when resistance emerged in Durban. A subsequent study 
carried out by the STI Reference Centre in several cities including Durban, Cape Town and 
Johannesburg showed varying levels of quinolone resistance but a general trend of increasing 
resistance to ciprofloxacin. Studies in Gauteng have also found high levels of tetracycline resistance 
which excludes its use as well as the use of penicillin, due to the reports of penicillinase-producing 
gonococci. The current first line therapy was changed from ciprofloxacin to cephalosporins in 2008, 
which showed good activity against N. gonorrhoea. Treatment is recommended as either oral 
cefixime or intramuscular ceftriaxone but while widespread resistance to these agents has not been 
reported in Africa, resistance to oral cephalosporins has emerged in the Western Pacific region as well 
as Europe, a trend which may spread to South Africa in the near future (Crowther-Gibson, et al., 
2011). In 2012 the first two cases of confirmed extended-spectrum-cephalosporin-resistant N. 
gonorrhoeae were reported in Johannesburg (Lewis et al. 2013 (b)). 
Other Research in South Africa 
Statistics from the Johannesburg Antimicrobial Resistance Laboratory and Culture Collection 
(AMRL-CC) of the Centre for Opportunistic, Tropical and Hospital Infections at the NICD describe 
CPE isolates. The majority of isolates were K. pneumoniae, E. coli and Serratia marcescens and the 
presence of these CPE isolates indicates the need for formal surveillance on a national level in order 
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to inform public health policy (Centre for Opportunistic, Tropical, and Hospital Infections, 2015). A 
study in five hospitals in the Eastern Cape, investigated carbapenem resistant Enterobacter cloacae 
and found that 72% of isolates harboured carbapenem resistance genes and strains from the same 
geographic location were genetically similar  (Singh-Moodley, et al., 2015).  
Both these studies indicate a cause for concern that the incidence of carbapenem resistance is 
increasing and that this resistance may be conferred by mobile genetic elements. These studies also 
provide confidence in the capacity South Africa has to conduct systematic surveillance and provide 
usable data for strategy development and that the implementation of WHO recommendations, as will 
be discussed below, are achievable based on the resources available. 
1.2.5. ABR surveillance in KwaZulu Natal 
A study was published in 2005 looking at data from 16 public hospitals in KwaZulu Natal including 
district, regional and tertiary hospitals and the resistance in isolates from the different levels of 
hospitals was compared. Ninety percent of isolates were found to be multi-drug resistant and the 
incidence of MRSA was 17 – 28% in district, regional and tertiary hospitals. Resistance to ampicillin 
was high (>80%) as compared to meropenem (<10%) according to the combined percentage 
resistance for all species included in the study (Essack et al., 2005). 
There are several public healthcare facilities in KZN which serve as sentinel surveillance sites 
including enhanced surveillance site such as Addington Hospital amongst others as mentioned above. 
These sites provide susceptibility data on a number of pathogens, including the ESKAPE pathogens 
and this information has been included in national surveillance reports (GERMS-SA, 2013) (Perovic, 
et al., 2014). 
The WHO established pilot projects in two cities in South Africa: Durban and Brits and each site 
implemented a protocol for collecting community-based AMR data every month for at least 
12 months, using one or two indicator bacteria. In Durban S. pneumoniae and H. influenzae were the 
indicators and resistance was measured in terms of the MIC values (Holloway, et al., 2011). 
A study conducted at Inkosi Albert Luthuli Central Hospital (IALCH) in 2009 investigated the 
susceptibility of nosocomial infections in the Trauma Intensive Care Unit (TICU) and reviewed the 
accuracy of empiric antibiotics. IALCH employs antibiotic stewardship and the study found that such 
programmes promoted rational use of antibiotics which in turn limit the progress of AMR. Many of 
the GLASS pathogens of interest were isolated during the study period. A. baumannii isolates were 
most susceptible to amikacin (43%), susceptibility in S. aureus isolates to clindamycin, cloxacillin, 
erythromycin, gentamicin and vancomycin was 62 -100% while only 11% and 16% susceptibility to 
penicillin and ampicillin was reported respectively. S. pneumoniae isolates showed 7% resistance to 
penicillin, 33% resistance to ampicillin and 100% resistance to cloxacillin. Susceptibility in E. coli 
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isolates was >80% for all antibiotics except amoxicillin-clavulanate (45%) while susceptibility in K. 
pneumoniae isolates was 58 – 92% for all antibiotics  (Ramsamy, et al., 2013). 
Although limited surveillance has been conducted specifically in KwaZulu Natal, data from 
surveillance sites in the province have contributed towards national surveillance studies. 
Antimicrobial susceptibility data is available from public sector hospitals via data from VITEK 
machines which carry out automated antimicrobial susceptibility testing (GERMS-SA, 2013). 
  1.2.6. Antimicrobial Susceptibility Testing (AST) 
In order to identify and quantify drug resistance in pathogens, there are various methods of carrying 
out susceptibility testing. The most common methods of AST are disc sensitivity testing, broth 
microdilution and rapid automated instrument methods. Each method has benefits and shortcomings 
and the accuracy of testing of certain organisms varies between methods (Barth Reller et al., 2009). 
Broth macrodilution includes preparing two-fold dilutions of antibiotics in a liquid growth medium 
and identifying the MIC after incubation. The benefit of this method is that a quantitative result is 
obtained, however this method is labour intensive and there is the possibility for human error. 
Microdilution works on the same principle, but the process in miniaturised and mechanised and 
multiple antibiotics can be tested on one tray. This method is that the results are reproducible, trays 
with prepared antibiotic panels are available and the cost of testing is relatively low (Barth Reller et 
al., 2009). 
Another method of testing is the antimicrobial gradient method whereby an antimicrobial 
concentration gradient in an agar medium is established. An example of this is the Etest which uses 
test strips impregnated with dried antibiotics of increasing concentration. After overnight incubation, 
MIC is determined based on the growth inhibition area. This method allows for the flexibility to 
choose which drugs to test, however the test strips are costly so it is not practical for testing multiple 
drugs. While the results from this method of testing are generally comparable with broth 
microdilution, there are some systematic biases to higher or lower MICs in certain antibiotic-pathogen 
combinations (Barth Reller et al., 2009). 
Disk diffusion involves applying a bacterial inoculum to a Mueller-Hinton agar plate and antibiotic 
disks of fixed concentration are placed on the inoculated surface. Results are determined from the 
diameter of the growth inhibition zone after incubation as per the interpretive criteria in CLSI/ 
EUCAST guidelines or as per the product insert for the disks. This method of testing produces 
qualitative results categorised as susceptible, intermediate or resistant instead of MIC values. The 
testing procedure is simple and requires no specialised equipment and it is the cheapest of all testing 
methods. The disadvantages are that not all bacteria can be accurately tested by this method and all 
preparation is manual (Barth Reller et al., 2009). 
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Automated microbiological testing provides pathogen identification and AST processing of specimens 
and is used to provide the necessary information for clinical interventions. Automated systems are a 
useful tool in antimicrobial surveillance and allows for easy acquisition of specimen analysis reducing 
the workload of the researcher. Automated instrument systems allow for rapid susceptibility testing 
and because computer software is used to interpret results, the reading of endpoints is standardised. 
The disadvantage is that there is a lessened ability to detect resistance in certain cases such as 
vancomycin resistance and inducible β-lactamases. An example of an automated testing system in the 
VITEK 2 machine, which is the method used for susceptibility testing in this study (Ligozzi, et al., 
2002) (Barth Reller et al., 2009). 
The VITEK 2 machine uses reagent cards with 64 wells containing a test substrate meaning that a 
single card can hold up to 64 organism-substrate combinations. The pure culture for analysis first 
needs to be prepared as a suspension before it can be inserted into the Vitek machine for inoculation 
and incubation. The incubator can hold up to 60 cards at a time and readings are collected by the 
machine at 15minute intervals. MIC results are displayed as “+” or “-” based on automatic 
calculations done on the raw data that are compared to test thresholds  (Ligozzi, et al., 2002). 
The VITEK 2 system has been shown to provide accurate identification and AST results for use in 
hospitals where microbiological testing is in high demand and results are needed rapidly. This is 
especially useful in resource-limited settings where there may not be sufficient human resources to 
conduct manual microbiological testing for clinical use (Ligozzi, et al., 2002). 
1.3. Conclusion 
With the escalation of multi-drug resistant infections, treatment options are becoming more limited, 
making commonly encountered infections increasingly difficult to treat. The purpose of this study was 
to illustrate antibiotic resistance trends in pathogen-drug combinations stipulated in GLASS in the 
province of KwaZulu Natal, South Africa over a 5-year period. 
 It is clear from the literature that while surveillance systems do exist, there is variability in the quality 
and reliability of data and differences in methodology, pathogens and drugs of interest hinder the 
establishment of the true extent of ABR.  Specifically, surveillance in Africa is less well established 
than in other regions such as Europe, North America and Australia and inadequate funding, human 
resources and infrastructure limit the capacity for surveillance in under-resourced countries. As such, 
there is a great need for surveillance in order to obtain information on the true extent of antibiotic 
resistance in the region. 
The GLASS manual for early implementation provides data compilation methods, resistance markers 
for global reporting and a stepwise implementation plan that allows for the gradual induction into the 
program. By applying the GLASS methodology, simplified data collection and reporting can be 
established to provide baseline information on the extent of ABR which can later be expanded once 
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the surveillance methodology is established. This study aims to address the gap in knowledge 
regarding ABR in GLASS pathogen-drug combinations to some extent.  The results can be used to 
guide future studies and build on the existing knowledge base to provide comparable, validated data 
which can be shared on a global scale in order to guide future interventions against the spread of 
ABR. 
1.4. Aims and objectives 
Aims: 
To elucidate the extent and trends in ABR in blood stream infections, urinary tract infections (UTIs), 
diarrhoea and gonorrhoea in KwaZulu Natal using guidelines delineated in the Global Antimicrobial 
Surveillance System (GLASS) of World Health Organisation (WHO) over the period 2011-2015. 
Objectives: 
 To create a database of blood stream infections (BSI), urinary tract infections (UTI), 
diarrhoeal infections and gonorrhoeal infections from extracted from the provincial database 
of the KwaZulu-Natal National Health Laboratory Services including but not limited to: 
o Causative bacteria and their associated antibiotic susceptibility profiles 
o Clinical data on specimen source, diagnosis (if available), date of admission, date of 
specimen collection, date of discharge etc. 
o Demographic data on age, gender, co-morbidity (if available).  
o Facility data such as hospital level and ward type 
 To identify the proportion of BSIs, UTIs, diarrhoeal infections and gonorrhoea caused by 
each pathogen of interest. 
 To observe any changes/trends in the proportion of causative pathogens for each specimen 
type per year. 
 To analyse the trends in ABR over the study period and identify changes in susceptibility 
profiles if evident.  
 To compare the susceptibility profiles obtained with the antibiotics recommended in the 
Standard Treatment Guidelines published by the Department of Health with a view to 
informing amendments per hospital level as appropriate. 
 To create a baseline for the WHO GLASS platform at provincial level 
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1.5. Dissertation Structure 
The dissertation is set out as follows: 
Chapter 1:  Introduction and Literature Review  
Chapter 2: Manuscript entitled “A Retrospective Trend Analysis of Antibiotic Resistance in GLASS 
Pathogens in KwaZulu Natal: 2011- 2015” intended for submission to the Bulletin of the World 
Health Organisation: 
Chapter 3: Conclusion, Limitations and Recommendations 
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Abstract 
Objective:  Antibiotic resistance trends in pathogen-drug combinations stipulated in the Global 
Antimicrobial Surveillance System (GLASS) of the World Health Organization were investigated for 
the period 2011-2015 in KwaZulu-Natal, South Africa. 
Methods: Antibiotic susceptibility data from blood, urine, faecal and urethral/cervical samples was 
retrospectively analyzed from six public hospitals. Pathogens included Escherichia coli, 
Streptococcus pneumoniae, Klebsiella pneumoniae, Salmonella spp., Acinetobacter baumannii, 
Staphylococcus aureus, Shigella spp. and N. gonorrhoea. Results included MIC50, MIC90, 
percentage resistance, incidence of infections in the population and proportion of non-susceptible 
infections. Results were also evaluated against South African treatment guidelines. Significant 
differences in resistance proportions by year were identified using the Pearson χ2 test. Comparison of 
MIC50 were analysed using the equality-of-medians test. 
Findings:  Urine samples were most abundant (61.22%, n= 33 018) and E. coli (52%) was the most 
common pathogen. Most isolates were multi-drug resistant and resistance to cephalosporins and 
fluoroquinolones increased in K. pneumoniae, E. coli and Shigella spp. Notable changes in resistance 
were: K. pneumoniae from blood samples to carbapenems (1 – 26%, p< 0.001) and A. baumannii to 
carbapenems (69% - 50%, no p-value). Susceptibility to antibiotics recommended in treatment 
guidelines was >50% for most pathogen-drug combinations. 
Conclusion: Although resistance in some pathogen-drug combinations plateaued or declined, 
antibiotic resistance in hospitals in KwaZulu-Natal increased from 2011 to 2015, necessitating a 
review of the existing treatment guidelines. To our knowledge, this is the first South African report on 
ABR using GLASS metrics. There is a need for more extensive research in order to build an accurate 
picture of ABR in South Africa.  
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Introduction 
Antibiotics are essential for treating bacterial infections however antibiotic resistance (ABR) has 
become a fast spreading phenomenon which is limiting treatment options for common infections. A 
key strategic objective of the Global Action Plan (GAP) on Antimicrobial Resistance (AMR), adopted 
by member states of the World Health Organisation (WHO) in 2015, is to strengthen the knowledge 
and evidence base through surveillance and research. Surveillance was highlighted as an important 
tool in mapping out the prevalence, trends and mechanisms of ABR to understand the extent of the 
problem on a global scale (1).  The 2014 surveillance report on antimicrobial resistance published by 
the WHO highlighted the scarcity of reliable data on ABR in Africa as not many countries in the 
region carry out surveillance compared to the relatively well-established surveillance systems found 
in the European region. Inadequate funding, human resources and infrastructure limit the capacity for 
surveillance in under-resourced countries (2).  As such, there is a great need for surveillance in order to 
obtain information on the true extent of antibiotic resistance in the region.  
ABR surveillance is more extensive in South Africa compared to other countries in the WHO Africa 
region.  Existing literature from both public and private sector facilities indicate a decline in efficacy 
of older antibiotics such as ampicillin and tetracycline and more recently, cephalosporins and 
fluoroquinolones. This has necessitated the increased use of carbapenems to treat resistant 
infections.(3) In addition, methicillin resistant Staphylococcus aureus (MRSA) as well as extended 
spectrum β-lactamase (ESBL) producing pathogens are prevalent. With the escalation of multi-drug 
resistant infections, treatment options are becoming more limited, making commonly encountered 
infections increasingly difficult to treat.  (4) 
While many countries are already conducting surveillance, there is a lack in uniformity in surveillance 
methods as well as the pathogens and antibiotics investigated.   In order for data to be meaningful and 
comparable on a global scale, the WHO published the Global Antimicrobial Surveillance System 
(GLASS) manual which aimed to standardise surveillance methods to yield validated data reported in 
a uniform manner. Specific pathogen-drug combination for four specimen types namely blood, urine, 
stool and cervical/urethral swabs, were outlined and WHO member states are encouraged to 
implement GLASS as far as possible in order to provide a baseline database of ABR on a global scale 
that can be built on as surveillance methods become more firmly established (2). 
The purpose of this study was to illustrate antibiotic resistance trends in pathogen-drug combinations 
stipulated in GLASS for the period 2011-2015 in six public hospitals in the province of KwaZulu 
Natal, South Africa from blood, urine, stool and cervical/urethral samples indicative of blood stream 
infections (BSIs), urinary tract infections (UTIs), diarrhoeal infections and gonorrhoeal infections 
respectively.  To our knowledge, this is the first South African report on ABR using GLASS metrics.    
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Methods 
Study Design 
Antibiotic susceptibility data from 2011 to 2015 was retrospectively extracted from the KwaZulu-
Natal National Health Laboratory Services (NHLS) computerized database from six public sector 
hospitals in KwaZulu Natal, South Africa and included all levels of care from the first point of contact 
at district level o the centralized, specialized care at tertiary and quaternary levels.  
The extracted de-duplicated data included specimen type, bacterial identity and antibiotic 
susceptibility results in the form of minimum inhibitory concentrations (MICs). The data was 
analysed to determine the trends in MICs and resistance in selected isolates during the study period. 
Only blood, urine and faecal samples positive for the pathogens of interest highlighted in the GLASS 
manual were included in the study. In terms of gonorrhoea, the data collected did not define urethral 
or cervical swabs as a specimen type and thus all Neisseria gonorrhoea specimens classified as 
“other” or with the specimen type missing were included. Priority pathogens for blood specimens 
included Escherichia coli, Streptococcus pneumoniae, Klebsiella pneumoniae, Salmonella spp., 
Acinetobacter baumannii and Staphylococcus aureus. Priority pathogens for urine samples were E. 
coli and K. pneumoniae. Priority pathogens for faecal samples were Salmonella spp. and Shigella spp. 
The population data for KwaZulu Natal required for the calculation of GLASS metrics was obtained 
from the results of the 2011 national census. (5) 
Ethical Considerations  
The study was approved by the Biomedical Research Ethics Committee (BREC) (REF: BE085/12).  
All data was anonymized in order to maintain patient confidentiality. 
Antimicrobial Susceptibility Testing 
Pathogen identification and susceptibility testing was carried out at each participating hospital on the 
VITEK 2 system (bioMerieux) according to the Clinical Laboratory Standards Institute (CLSI) 
guidelines and isolates were classified as sensitive or resistant using CLSI-approved breakpoints. 
Antibiotic panels per pathogen appear in Supplementary Table 1 as recommended by GLASS. 
External Quality Assurance 
The participating hospital laboratories subscribe to the NHLS Proficiency Testing Scheme (PTS) 
coordinated by the PTS Managers(Microbiology) at the NHLS Academic Affairs, Research and 
Quality Assurance(AARQA) Unit. The scheme entails quarterly evaluations for, amongst others, 
bacteriology. Microscopy, culture and identification methods and manual and automated 
antimicrobial susceptibility testing (AST) methods are evaluated based on samples prepared with the 
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assistance of the National Institute for Communicable Diseases (NICD) – Centre for Opportunistic, 
Tropical and Hospital Infections, a division of the NHLS. 
 
Statistical Analysis 
All data processing and analyses were performed using Stata 13.0 software SE (StataCorp. 2013. Stata 
Statistical Software: Release 13. College Station, TX: StataCorp LP.). Categorical GLASS pathogen 
data were presented using stratified frequency tables (n and %). Differences in MIC50 levels over the 
period of 2011-2015 were assessed using a non-parametric equality-of-medians test. Differences or 
trends or association for resistance types and year for example was assessed using the standard 
Pearson’s chi-square (χ2) test. If expected cell count in the cross tabulation contained fewer than 5 
observations (sparse numbers) then the Fishers exact test was utilized instead. A p-value of <0.05 was 
considered statistically significant.   
Results 
Table 1 illustrates the number of isolates per specimen type and pathogen between 2011 and 2015. 
Isolate numbers for 2014 are not accurate as six months of data from one of the participating hospitals 
was missing from the NHLS database.  The number of samples positive for any of the GLASS 
pathogens increased more than two-fold from 4 737 collected in 2011 to 10 289 collected in 2015. 
Blood (n=11 722) and urine (n=20 212) samples formed the vast majority of specimens.  The most 
frequently isolated pathogen was E. coli from urine specimens constituting 56.08% (n=33018) of the 
isolates over the five-year study period.  
  
41 
Table 1: Number of isolates per specimen type and pathogen between 2011 and 2015 
(percentage indicated in parenthesis) 
Specimen Type 2011 2012 2013 2014 2015 Total P-value* 
Blood 1792 (37.83) 2391 (37.26) 2823 (37.42) 1353 (33.56) 3363 (32.69) 11722 (35.50) <0.001 
 E. coli 397 (8.38) 441 (6.87) 417 (5.53) 221 (5.48) 609 (5.92) 2085 (6.31) <0.001 
 K. pneumoniae 373 (7.87) 577 (8.99) 698 (9.25) 358 (8.88) 1053 (10.23) 3059 (9.26) <0.001 
 A. baumanii 248 (5.24) 341 (5.31) 483 (6.4) 147 (3.65) 353 (3.43) 1572 (4.76) <0.001 
S. aureus 543 (11.46) 773 (12.05) 890 (11.8) 471 (11.68) 1110 (10.79) 3787 (11.47) <0.001 
S. pneumoniae 188 (3.97) 179 (2.79) 238 (3.15) 118 (2.93) 170 (1.65) 893 (2.7) <0.001 
Salmonella spp. 43 (0.91) 80 (1.25) 97 (1.29) 38 (0.94) 68 (0.66) 326 (0.99) <0.001 
Urine 2808 (59.28) 3859 (60.15) 4451 (58.99) 2494 (61.87) 6600 (64.15) 20212 (61.22) <0.001 
E. coli  2202 (46.49) 2936 (45.76) 3257 (43.17) 1907 (47.31) 4913 (47.75) 15215 (46.08) <0.001 
K. pneumoniae 606 (12.79) 923 (14.39) 1194 (15.83) 587 (14.56) 1687 (16.40) 4997 (15.13) <0.001 
Faeces 102 (2.15) 142 (2.22) 237 (3.14) 163 (4.04) 272 (2.64) 916 (2.77) <0.001 
Salmonella spp. 47 (0.99) 46 (0.72) 78 (1.03) 46 (1.14) 82 (0.80) 299 (0.91) <0.001 
Shigella spp. 55 (1.16) 96 (1.50) 159 (2.11) 117 (2.90) 190 (1.85) 617 (1.87) <0.001 
Urethral/cervical 35 (0.74) 24 (0.37) 34 (0.45) 21 (0.52) 54 (0.52) 168 (0.51) <0.001 
 N. gonorrhoea 35 (0.74) 24 (0.37) 34 (0.45) 21 (0.52) 54 (0.52) 168 (0.51) <0.001 
Total 4737 (100) 6416 (100) 7545 (100) 4031 (100) 10289 (100) 33018 (100)   
*Pearson’s chi2 p-value 
 
Antibiotic Resistance 
The antibiotic resistance data was stratified by year and analysed on 3 levels: (1) a trend analysis of 
resistance including MIC50, MIC90, MIC range and percentage resistance over 5 years was 
conducted; (2) metrics recommended in the GLASS manual were calculated and (3) susceptibility 
data was compared with existing standard treatment guidelines.  Table 2 illustrates the AST results 
over the study period for each specimen type (See Supplementary Table 2 for overall AST results for 
the study period).  
The trends in resistance observed over the five years varied between the different pathogen-drug 
combinations. While the percentage resistance across most pathogen-drug combinations increased 
from 2011 to 2015, the MIC50 and MIC90 remained stable, with changes observed in only a few 
pathogen-drug combinations.  K. pneumoniae isolates showed the most changes in MIC50 with 
statistically significant increases in MIC50 in isolates from urine samples for ceftazidime (≤1µg/ml – 
8µg/ml, p= < 0.001), cefotaxime (≤ 1µg/ml - ≥ 64µg/ml, p < 0.001) and cefepime (≤1µg/ml – 2µg/ml, 
p< 0.001). Other pathogen-drug combinations that showed fluctuations in MIC50 were A. baumannii 
for -  amikacin (4µg/ml – 8µg/ml, p= 0.001), gentamicin (≥16µg/ml – 8µg/ml, p-value not available) 
and imipenem (≥16µg/ml - ≤1µg/ml, p-value not available); E. coli from urine samples for imipenem 
(≤1µg/ml - ≤0.25µg/ml, p< 0.001); Salmonella spp. from faeces for cefotaxime (4µg/ml  - ≤1µg/ml, 
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p< 0.001). These changes in MIC50 corroborated the changes in percentage resistance observed. The 
majority of pathogens showed an increase in percentage resistance from 2011 to 2015, with the 
exception of A. baumannii isolates from blood samples as well as Salmonella spp. isolates from both 
blood and faecal samples. All A. baumannii isolates showed a decrease in resistance to all the 
antibiotics tested while Salmonella spp. isolates showed a decrease or plateau in resistance to all 
antibiotics tested except for ciprofloxacin in isolates from blood samples which only showed a 0.33% 
increase in resistance. A statistically significant (p ≤ 0.05) increase in percentage resistance between 
2011 and 2015 was observed in the following pathogen-drug combinations: E. coli isolates from 
blood samples for ceftazidime, cefotaxime, ciprofloxacin, imipenem; K. pneumoniae isolates from 
blood samples for ciprofloxacin, cefepime, ertapenem, imipenem, meropenem; E. coli isolates from 
urine samples for ceftazidime, cefotaxime, ertapenem, cefepime; K. pneumoniae isolates from urine 
samples for ceftazidime, ceftazidime, cefepime, ertapenem, imipenem, meropenem; and, Salmonella 
spp. isolates from faecal samples for ciprofloxacin. The escalating resistance to the broad spectrum 
cephalosporins, carbapenems and fluoroquinolones was evident.   A statistically significant (p ≤ 0.05) 
decrease in resistance between 2011 and 2015 was observed in the following pathogen-drug 
combinations: Salmonella spp. isolates from blood samples – ciprofloxacin, cefotaxime, ertapenem; 
Salmonella spp. isolates from faecal samples – cefotaxime, ceftazidime, ertapenem.   
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Table 2: AST Results by Year 2011 – 2015  
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45 
AM- Ampicillin, CAZ- Ceftazidime, CIP- Ciprofloxacin, CS- Colistin, CTX- Cefotaxime, ETP- Ertapenem, FEP- Cefepime, IPM-   
Imipenem, MEM- Meropenem, SXT- Trimethoprim-sulfamethoxazole, AN- Amikacin, GM- Gentamicin, TGC- Tigecycline, FOX- 
Cefoxitin, OX1- Oxacillin, P- Penicillin (CLSI Breakpoint for non-meningitis S. pneumoniae ) 
* CLSI Breakpoint not available 
**Pearson chi-square p-values 
Note: MIC50 p-values are based on the results of a non-parametric equality-of-medians test. 
 
The following GLASS metrics were generated: proportion of non-susceptible samples out of all 
samples positive for GLASS pathogens, number of infections caused by GLASS pathogens per 
specimen type per 100 000 inhabitants, number of infections caused by GLASS pathogens per 
organism per 100000 inhabitants and number of resistant infections per pathogen and drug per 100 
000 inhabitants.  
 
Table 3 illustrates the proportion of non-susceptible samples out of all samples positive for selected 
GLASS pathogens (See Supplementary Table 3 for all pathogens). While Table 2 reflects the 
percentage resistance with the total number of positive samples per pathogen-drug combination as a 
denominator, Table 3 reflects the resistance rates with the total number of samples positive for 
GLASS pathogens per specimen type as a denominator. Table 3 serves to illustrate the trends in 
resistance within each specimen type. A statistically significant increase in the proportion of E. coli 
from blood that were non-susceptible to ceftazidime, cefotaxime, ciprofloxacin and 
trimethoprim/sulfamethoxazole was evident as was the increase in the proportion of non-susceptible 
K. pneumoniae against all antibiotics tested.  A statistically significant increase in the proportion of 
Salmonella spp. from faeces that were non-susceptible to ceftazidime, cefotaxime, ciprofloxacin and 
ertapenem was also observed.  Out of 69 pathogen-drug combinations, only 19 had no resistant 
isolates in at least one year between 2011 and 2015. Most of the pathogens were multi-drug resistant 
i.e. resistant to three or more classes of antibiotics. E. coli, K. pneumoniae, A. baumannii, Salmonella 
spp. and S. pneumoniae were multi-drug resistant (S. aureus, Shigella spp. and N. gonorrhoea were 
tested against less than 3 classes of antibiotics).  An escalation of ABR elucidated by GLASS metrics 
confirmed the general increase in ABR resistance trends described above. 
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Table 3: Proportion of non-susceptible samples out of all samples positive for GLASS pathogens 
per specimen type 2011-2015 
 
  
* AM- Ampicillin, CIP- Ciprofloxacin, CTX- Cefotaxime, CAZ- Ceftazidime, FEP- Cefepime, IPM-   Imipenem, ETP- 
Ertapenem, MEM- Meropenem, SXT- Trimethoprim-sulfamethoxazole 
**Fisher’s exact p-value, all others are Pearson chi-square p-values  
 
Table 4 illustrates the number of resistant infections for one pathogen per specimen type per 100 000 
inhabitants. (See Supplementary Table 4 for all pathogens). The number of resistant infections per 
100 000 inhabitants generally increased across all pathogen-drug combinations with the exception of 
Salmonella spp. from faecal samples noting that relatively few faecal samples were included in the 
Blood: E. coli   Urine: K. pneumoniae 
  2011 2012 2013 2014 2015 P-value     2011 2012 2013 2014 2015 P-value 
AM* 6,98 6,23 6,77 9,83 6,13 0   CAZ 3,92 5,52 6,07 8,86 6,64 <0.001 
CAZ 0,89 1,34 0,99 1,85 1,87 0.007   CIP 3,99 5,18 5,14 7,46 5,35 <0.001 
CIP 1,73 1,97 2,09 3,33 2,68 0.013   CTX 4,77 6,04 7,01 10,18 7,41 <0.001 
CTX 1,23 2,01 1,74 3,33 2,77 <0.001   ETP 0,07 0,31 0,38 0,64 1,48 <0.001** 
ETP 0,00 0,04 0,00 0,15 0,06 0.197**   FEP 1,21 2,62 2,76 4,29 3,97 <0.001 
FEP 0,45 0,71 0,39 0,96 0,74 0.143   IPM 0,14 0,21 0,13 0,52 1,29 <0.001** 
IPM 0,00 0,13 0,00 0,00 0,12 0.131**   MEM 0,14 0,16 0,36 0,56 1,39 <0.001** 
MEM 0,00 0,08 0,04 0,00 0,06 0.818**   SXT 7,91 8,84 9,23 13,43 8,62 <0.001 
SXT 7,14 6,27 6,41 9,09 4,79 <0.001   Total 
GLASS 
pathogens 
2808 3859 4451 2494 6600   
Total 
GLASS 
pathogens 
1792 2391 2823 1353 3363                   
Faeces: Salmonella spp.   N. gonorrhoea 
  2011 2012 2013 2014 2015 P-value     2011 2012 2013 2014 2015 P-value 
CAZ 2,94 1,41 0 0 0,37 0.010**   CIP  0 0 0 0 1.85 - 
CIP 4,90 9,15 14,35 4,29 3,31 <0.001   Total 
GLASS 
pathogens 
35 24 34 21 54   
CTX 13,73 1,41 0 0 0,74 <0.001**                 
ETP 10,78 0 0 0 0 <0.001**                 
IPM 0 0 0 0 0 -                 
MEM 0 0 0 0 0 -                 
Total 
GLASS 
pathogens 
102 142 237 163 272                   
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study (n=916) and Salmonella spp./ciprofloxacin was the only pathogen-drug combination for which 
resistant isolates were identified every year in the study period. Between 2011 and 2015 UTIs and 
BSIs were the most common infections causing 197 and 119 infections per 100 000 inhabitants 
(n=10 267 300) respectively while the most common causative pathogen was E. coli from urine 
samples, causing 148 infections per 100 000 inhabitants (n= 10 267 300). In BSIs, S. aureus caused 
the most number of infections (37 per 100 000 inhabitants, n= 10 267 300) while in the most common 
cause of diarrhoeal infections was Shigella spp. (6 per 100 000 inhabitants, n= 10 267 300). E. coli 
isolates from urine samples were responsible for the most number of resistant infections (75 per 
100 000 inhabitants resistant to ampicillin, n= 10 267 300) while K. pneumoniae infections resistant 
to trimethoprim-sulfamethoxazole were most common among BSIs (10 per 100 000 inhabitants, n= 
10 267 300). Diarrhoeal infections were most commonly caused by Salmonella spp. isolates resistant 
to ciprofloxacin (1 per 100 000 inhabitants, n= 10 267 300). 
 
Table 4: Number of Resistant infections per pathogen and drug per 100 000 inhabitants 
 
Blood: E. coli Urine: K. pneumoniae 
 2011 2012 2013 2014 2015 p-
value* 
 2011 2012 2013 2014 2015 p-value* 
AM 1,22 1,45 1,86 1,30 2,01 <0.001        
CAZ 0,16 0,31 0,27 0,24 0,61 0,00 CAZ 1,07 2,07 2,63 2,15 4,27 <0.001 
CIP 0,30 0,46 0,57 0,44 0,88 <0.001 CIP 1,09 1,95 2,23 1,81 3,44 <0.001 
CTX 0,21 0,47 0,48 0,44 0,91 <0.001 CTX 1,31 2,27 3,04 2,47 4,76 <0.001 
ETP 0,00 0,01 0,00 0,02 0,02 0,18 ETP 0,02 0,12 0,17 0,16 0,95 <0.001 
FEP 0,08 0,17 0,11 0,13 0,24 0,09 FEP 0,33 0,98 1,20 1,04 2,55 <0.001 
IPM 0,00 0,03 0,00 0,00 0,04 0,16 IPM 0,04 0,08 0,06 0,13 0,83 <0.001 
MEM 0,00 0,02 0,01 0,00 0,02 0,82 MEM 0,04 0,06 0,16 0,14 0,90 <0.001 
SXT 1,25 1,46 1,76 1,20 1,57 <0.001 SXT 2,16 3,32 4,00 3,26 5,54 <0.001 
Faeces: Salmonella spp. N. gonorrhoea 
 2011 2012 2013 2014 2015   2011 2012 2013 2014 2015  
CAZ 0,03 0,02 0,00 0,00 0,01 0,06        
CIP 0,05 0,13 0,33 0,07 0,09 <0.001 CIP 0,00 0,00 0,00 0,00 0,01 NC 
CTX 0,14 0,02 0,00 0,00 0,02 <0.001        
ETP 0,11 0,00 0,00 0,00 0,00 <0.001        
IPM 0,00 0,00 0,00 0,00 0,00 NC        
MEM 0,00 0,00 0,00 0,00 0,00 NC Total Population: 10 267 300 
        
* Pearson chi-square p-value 
NC- Not calculated 
 
Resistance data was also compared to the standard treatment guidelines available in South Africa, 
published by the National Department of Health and the Federation of Infectious Diseases Societies of 
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Southern Africa (FIDSSA). Table 7 shows the proportion of infections that would be treatable using 
the antibiotics recommended by these guidelines. The antibiotics in the Table are those used in the 
Vitek 2 panel of antibiotics.  In UTIs, only two thirds of the infections caused by E. coli and K. 
pneumoniae could be successfully treated by ciprofloxacin and amoxicillin-clavulanate, which are the 
first line agents recommended in the treatment guidelines. Nitrofurantoin showed only a 31% 
susceptibility against UTIs caused by K. pneumoniae. Ciprofloxacin, the recommended first line 
treatment for diarrhoeal infections, would only treat 75% of infections caused by Salmonella spp., 
however, 99% of diarrhoeal infections caused by Shigella spp. were shown to be treatable with 
ciprofloxacin. 
Table 5: Percentage of Infections Susceptible to Antibiotics Recommended as per Treatment 
Guidelines 
Blood Stream Infections* Cloxacillin Vancomycin Ceftriaxone Gentamicin Clindamycin 
S. aureus - 96.79% 
(n=1368) 
- - 96.85% 
(n= 1367) 
E. coli - - - 80.13% 
(n= 936) 
- 
K. pneumoniae  - - - 40.72% 
(n= 1196) 
- 
S. pneumoniae - - - N/A - 
A. baumannii - - - 37.45% 
(n= 745) 
- 
Salmonella spp. - - - N/A - 
Urinary Tract Infections ** Ciprofloxacin Amoxicillin-
clavulanate 
Gentamicin Fosfomycin Nitrofurantoin 
E. coli 68.31% 
(n-953) 
67.15% 
(n=9397) 
85.37% 
(n=9399) 
- 87.41% 
(n=9383) 
K. pneumoniae 62.67% 
(n=2893) 
50.98% 
(n=2864) 
59.01% 
(n=2776) 
- 30.87% 
(n=2860) 
      
Diarrhoeal Infections ** Ciprofloxacin 
    
Salmonella spp. 75.54% 
(n=145) 
    
Shigella spp. 99.06% 
(n=319) 
    
      
Gonorrhoea* Ceftriaxone Azithromycin 
   
N. gonorrhoea - - 
   
* SAASP Guidelines (Wasserman, et al., 2015) 
** Government published Standard Treatment Guidelines (Department of Health Republic of South Africa, 2015) 
-  Pathogen-drug combination not included in study or no samples found for pathogen-drug combination 
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Discussion: 
Antibiotic resistance trends were investigated in pathogen-drug combinations stipulated in GLASS for 
the period 2011-2015 in six public hospitals in the province of KwaZulu Natal, South Africa in 
putative BSIs, UTIs, diarrhoeal infections and gonorrhoeal infections.  The antibiotic resistance data 
was stratified by year and analysed on 3 levels: (1) a trend analysis of resistance including MIC50, 
MIC90, MIC range and percentage resistance over 5 years was conducted; (2) selected metrics 
recommended in the GLASS manual were calculated and (3) susceptibility data was compared with 
existing standard treatment guidelines.   
We generated a database of MIC and percentage resistance data including the majority of pathogen-
drug combinations listed in the GLASS manual. From this data we were able to observe a general 
increase in percentage resistance during the study period in the majority of pathogen-drug 
combinations, calculate the proportion of infections caused by each pathogen of interest, calculate the 
rate of resistance in terms of the population in KwaZulu Natal and correlate the resistance rates with 
existing treatment guidelines in South Africa. 
In South Africa diarrhoeal diseases and sexually transmitted infections (STIs) are major concerns, the 
former because it is one of the leading causes of infant mortality and the latter because it increases the 
risk of HIV infection (6).  UTIs are amongst the most common infections encountered in both the 
community and hospital setting and the emergence of resistance in various bacterial species has 
become a concern worldwide. BSIs are one of the leading nosocomial infections leading to poor 
treatment outcomes especially in children. In addition to the clinical importance of these infections, 
blood, urine, faecal and urethral/cervical samples are relatively easy to collect on a routine basis 
which is why these infections were identified for inclusion in the early implementation of GLASS. 
Existing ABR surveillance in South Africa has shown a decline in efficacy of older antibiotic drugs 
such as ampicillin and tetracycline and the emergence of resistance to carbapenems. In BSIs 
methicillin resistant Staphylococcus aureus (MRSA) as well as extended spectrum β-lactamase 
(ESBL) producing pathogens are prevalent, while in terms of diarrhoeal infections resistance to 
fluoroquinolones and third generation cephalosporins is increasing (3). In UTIs there is increasing 
resistance to third generation cephalosporins and carbapenems and in gonorrhoeal infections first line 
treatment was changed to oral or intramuscular cephalosporins due to resistance to ciprofloxacin (4)(7). 
We observed similar resistance trends in our study.   
In order to address the problem on AMR, South Africa is amongst the few African countries to have a 
national AMR strategy framework and the only country with laboratory-based surveillance (6) (8) with 
ABR research on the increase. The Centre for Healthcare Associated Infections, Antimicrobial 
Resistance and Mycoses, a branch of the NICD, conducts laboratory based antimicrobial resistance 
surveillance (LARS) and.  It was established in 2010 and collects data from sentinel sites.  Electronic 
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surveillance was implemented in 2013 and collects data from laboratory information systems in order 
to generate resistance maps. Enhanced surveillance has been implemented for methicillin-resistant S. 
aureus (MRSA) in order to determine the prevalence and extent of nosocomial and community-
acquired MRSA infections. Enhanced surveillance is also underway for carbapenem-resistant 
Enterobacteriaceae (CREs). (9) 
The results of this study were stratified, as per GLASS requirements, according to specimen type and 
pathogen-drug combination. These included BSIs, UTIs, diarrhoeal infections and gonorrhoeal 
infections. The total number of isolates increased more than two-fold from 4737 in 2011 to 10289 in 
2015, which could indicate that there is an increase in the use of AST results to guide treatment and 
rational prescribing. Isolates from blood and urine samples comprised 96.72% (n=33018) of the 
samples included in the study, suggesting a focus on the treatment of bacteraemia and UTIs guided by 
AST results. Treatment guidelines published by the South African National Department of Health 
recommends symptomatic management of acute diarrhoea and only recommends antibiotic therapy in 
severe cases or where there is a co-morbidity.  Gonorrhoeal infections are similarly managed 
empirically which could explain the limited number of isolates from faecal and urethral or cervical 
samples. (10) (11)  
Of the isolates obtained from blood samples, S. aureus was the most commonly isolated pathogen 
followed by K. pneumoniae and E. coli. While over 3000 S. aureus isolates were identified, only 29 
were tested against cefoxitin, the antibiotic recommended in the GLASS manual, and the percentage 
resistance was not calculated as there is no listed CLSI MIC breakpoint for this pathogen-drug 
combination. As such, resistance in S. aureus isolates will be discussed with reference to the MIC 
data. 
As a common cause of nosocomial infections with a known prevalence of multi-drug resistance, 
existing data has shown that A. baumannii is becoming increasingly difficult to treat. A study 
published in 2012 by Ballot et al. reported that A. baumannii was the third most common cause of 
sepsis-related deaths in neonates in a public hospital in Johannesburg, South Africa. (12) Crowther-
Gibson et al. reported that only 20 – 40% of A. baumannii infections were susceptible to carbapenems 
in public hospitals in South Africa in 2009 and that in the private sector, the use of carbapenems was 
becoming necessary due to increasing resistance to fluoroquinolones and third generation 
cephalosporins. The same paper reported that in the private sector, resistance in A. baumannii to 
imipenem and meropenem was already approximately 33% in 2006. (7)  It is encouraging to note that 
resistance to all antibiotics in A. baumannii isolates in this study declined between 2011 and 2015 and 
that colistin and amikacin showed sensitivity of 94% and 89% respectively in 2015. A study 
conducted in a trauma intensive care unit in Durban, South Africa, in 2009 reported that A. baumannii 
isolates were most susceptible to amikacin, with 43% of isolates being susceptible, suggesting that 
susceptibility of A. baumannii to amikacin has since improved.  A. baumannii isolates showed an 18 – 
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20% decrease in resistance to carbapenems and gentamicin, however, the percentage resistance to 
these antibiotics in 2015 was still in the region of 50%. These figures are slightly lower than those 
reported from sentinel public hospitals in South Africa in 2014 carried out by Perovic et al., which 
reported 66% and 77% resistance to gentamicin and carbapenems respectively and the 2009 study 
carried out by Ramsamy et al. which reported 87% and 90% resistance in A. baumannii isolates to 
gentamicin and meropenem respectively. (13) (14)  
S. aureus is a common pathogen isolated in humans and is a leading cause of nosocomial bacteraemia 
and more recently there have been reports of MRSA isolates from the community which is a cause for 
increased concern. Fortuin de-Smit et al. reported that MRSA was associated with higher mortality 
than methicillin sensitive S. aureus and that MRSA isolates were more likely to be resistant to 
multiple antibiotics from multiple classes. (15) In 2006 the incidence of MRSA was reported to be 36% 
based on data from 5 private hospitals while Ballot et al. reported that 70% of S. aureus isolates were 
methicillin resistant from blood cultures from neonates at a public hospital South Africa between 
2009 and 2010. Perovic et al. also reported methicillin resistance in 46% of S. aureus isolates from 
blood samples between 2010 and 2012 in 13 public hospitals around South Africa. (3) (7) (12) Data from 
the public sector obtained in 2009 indicated that S. aureus isolates from blood cultures showed a 16 – 
76%, 11 – 83% and 28 – 85% susceptibility to cloxacillin, erythromycin and clindamycin 
respectively. Results from the Ramsamy et al. study in trauma intensive care unit patients reported a 
relatively high susceptibility of S. aureus isolates to clindamycin, cloxacillin, erythromycin, 
gentamicin and vancomycin (62 -100%) while only 11% and 16% susceptibility to penicillin and 
ampicillin was reported. (7) (14) The results the Perovic et al. study published in 2015 showed that while 
99.8% of methicillin sensitive S. aureus isolates were sensitive to cefoxitin, only 5% of MRSA 
isolates were susceptible. Cefoxitin was the only antibiotic included in the study for S. aureus isolates 
as it is a surrogate for testing susceptibility to oxacillin, meaning it is a means of detecting MRSA. 
Fernandes et al. suggested in a study published in 2005 that cefoxitin resistance could be an easier 
method of detection methicillin resistance as opposed to the detection of the mecA gene by PCR, 
which is costly and requires specialised equipment. (2) (16 The Vitek 2 system provides results of a 
cefoxitin screen instead of MIC50 and MIC90 readings. A positive cefoxitin screen implies that the 
isolate is MRSA. Regrettably we were unable to extract and include this data in the results and it is an 
important limitation that should be addressed in future studies. S. pneumoniae is the leading cause of 
community-acquired pneumonia but is also the cause of invasive diseases such as bacterial meningitis 
and sepsis which are associated with high mortality. Resistance to penicillin and other β-lactam 
antibiotics in S. pneumoniae has been associated with poor clinical outcomes in patients with 
pneumococcal meningitis, but the implication is less apparent in terms of BSIs. The WHO 
Antimicrobial Resistance Global Report on Surveillance 2014 report mentions that further resistance 
data is required in order to establish the effect of reduced susceptibility to penicillins on clinical 
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outcomes in patients with BSIs. The report noted that in the Africa region, 3% of invasive S. 
pneumoniae (including BSIs and meningitis) isolates showed resistance to penicillin while Ramsamy 
et al. reported that S. pneumoniae isolates from the trauma intensive care unit showed 7% resistance 
to penicillin, 33% resistance to ampicillin and 100% resistance to cloxacillin. (14) (17) In this study AST 
results were included for S. pneumoniae isolates from blood samples against cefotaxime, oxacillin, 
benzylpenicillin and trimethoprim-sulfamethoxazole. As compared to the other pathogens included in 
the study, antimicrobial susceptibility data for S. pneumoniae was minimal for the GLASS antibiotic 
panel, with only 11, 5 and 16 isolates tested against cefotaxime, penicillin and trimethoprim-
sulfamethoxazole respectively. Oxacillin is used to screen for penicillin non-susceptibility in S. 
pneumoniae, thus there is no CLSI breakpoint for this pathogen-drug combination. Between 2011 and 
2015, only one isolate each was found to be resistant to cefotaxime and penicillin while 100% 
resistance was found to trimethoprim-sulfamethoxazole. 
K. pneumoniae is a common cause of UTIs and BSIs and is also a major cause of carbapenem 
resistant infections. K. pneumoniae is also reported to have the highest prevalence of resistance to 
third and fourth generation cephalosporins out of all of the Enterobacteriaceae. Ballot et al. found that 
K. pneumoniae was the second most common cause of BSIs in neonates at a public hospital in South 
Africa with 65% of these isolates being ESBL positive. (12) In terms of UTIs, K. pneumoniae isolates 
showed the most notable increase in resistance to all antibiotics except trimethoprim-
sulfamethoxazole, with the greatest increase in resistance being a 17% increase in resistance to 
cefepime. Resistance to carbapenems in isolates from urine samples increased from ≤ 1% in 2011 to 
10% in 2015 and increased by more than 20% in isolates from blood samples. This is more than 
double the figure of 3-5% resistance to carbapenems reported by Perovic et al. in 2014, while the 
WHO Antimicrobial Resistance Global Report on Surveillance 2014 reported 0 – 4% resistance to 
carbapenems in the Africa Region. K. pneumoniae isolates from blood samples showed an increase in 
resistance of 18% or more to all the antibiotics with the exception of trimethoprim-sulfamethoxazole. 
These findings are similar to those reported by Perovic et al. in their study of resistance in K. 
pneumoniae isolates from national sentinel site surveillance in South Africa between 2010 and 2012 
which reported that the majority of isolates were ESBL positive and were resistant to third and fourth 
generation cephalosporins. Resistance to the cephalosporins was found to be in the region of 70% 
with the exception of cefoxitin, which displayed high sensitivity (>80%) along with the carbapenems, 
amikacin, colistin, tigecycline and fosfomycin. It is apparent from the results of this study that 
carbapenem resistance in K. pneumoniae isolates is increasing with an 8 – 11% and a 23 – 25% 
increase in resistance to carbapenems in isolates from urine and blood samples respectively. (6) (13) (17) 
E. coli is the most common cause of both community and hospital acquired UTIs and is a common 
cause of BSIs. In this study E. coli isolates accounted for 52% of the isolates, mainly from urine 
samples. The WHO Antimicrobial Resistance Global Report on Surveillance 2014 showed 2 – 70% 
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portion of resistance in E. coli isolates to third generation cephalosporins and 14 – 71% resistance to 
fluoroquinolones from national data from the Africa Region. More specifically, the data from AMR 
surveillance conducted at sentinel public hospitals in South Africa in 2014 reported a 24% resistance 
to third generation cephalosporins and cefepime, a fourth-generation cephalosporins. (13)  It was 
reported by Ballot et al. that all but one of the E. coli isolates from blood cultures from neonates at a 
public hospital in South Africa were resistant to ampicillin, although all isolates were found to be 
susceptible to third generation cephalosporins and aminoglycosides. (12) The results of this study show 
that resistance to ampicillin was >80% in isolates from urine and blood samples by 2015 and that 
there was an increase in resistance in isolates from blood samples from 18% to 27% for ceftazidime 
and 26% to 40% for ceftriaxone between 2011 and 2015. Resistance to cefepime was found to be 
lower than the figure reported from 2014 surveillance data with a reported resistance of 11%. (17)  
Resistance in isolates from urine samples was found to be lower than in isolates from blood samples 
with a 13% resistance to ceftazidime, 23% resistance to ceftriaxone and 8% resistance to cefepime in 
2015. Susceptibility to carbapenems was found to be >90% in isolates from blood and urine samples 
which is consistent with the findings of Ramsamy et al. in 2009. (14)  Coetzee et al. reported in 2016 
that increasing colistin resistance in E. coli isolates is becoming a serious concern and that the use of 
colistin as a last resort is becoming more common due to resistance to other antibiotics. Resistance is 
thought to be spread by the presence of the mcr-1 gene in food animals such as pork and poultry, the 
presence of which has been confirmed by surveillance of poultry operations in South Africa. The mcr-
1 gene has also been detected in colistin-resistant E. coli in hospitalised and outpatient-based patients 
in South Africa. The percentage resistance data for E. coli and colistin was not calculated as there is 
currently no CLSI breakpoint for this pathogen-drug combination and the MIC50 and MIC90 results 
remained stable throughout the study period, however, future studies should monitor resistance in this 
pathogen-drug combination as resistance to colistin would severely limit treatment options in multi-
drug resistant E. coli infections. (18) 
Salmonella spp. pathogens are a common cause of foodborne illnesses such as gastroenteritis and 
enteric fever in the case of the Salmonella enterica serotypes Typhi and Paratyphi. Shigella spp. is 
also major cause of diarrhoeal infections which can be life threatening in children, especially in 
developing countries. The 2015 GERMS-SA Annual Report identified resistance to ciprofloxacin in 
Salmonella typhi as well as the emerging resistance to fluoroquinolones in Shigella spp. as a 
concern.(8) This was also highlighted in the WHO Antimicrobial Resistance Global Report on 
Surveillance 2014 which stated a 0 – 35% and a 0 – 3% proportion of resistance to fluoroquinolones 
in non-typhoidal Salmonella and Shigella spp. respectively.(17) Ciprofloxacin is the antibiotic 
recommended in the standard treatment guidelines in South Africa for acute diarrhoeal infections 
caused by Salmonella spp. and Shigella spp. Resistance of Shigella spp. isolates increased from 
0%(n=22) in 2011 to 2%(n=108) in 2015, which is comparable to the 1% resistance reported in the 
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GERMS-SA 2015 Annual Report. Salmonella spp. isolates from both blood and faecal samples 
showed either a decrease in resistance or no net change in resistance to all antibiotics and showed a 
considerable decrease in resistance of 50% to cefotaxime in isolates from faecal samples.  In 2015, the 
resistance of Salmonella spp. isolates to ciprofloxacin was 12%, which is less than the figure reported 
in the GERMS-SA 2015 report of 14% in S. typhi isolates and 21% in non-typhoidal Salmonella 
isolates. (8)  
As an STI, gonorrhoea is a public health concern in South Africa due to the associated increased risk 
of HIV infection. Resistance to first line therapy for gonorrhoea resulted in the change from 
ciprofloxacin to cephalosporins in 2008, however, the WHO Antimicrobial Resistance Global Report 
on Surveillance 2014 reported a decreased in susceptibility to third generation cephalosporins in the 
Africa Region in 2014.(17) In this study only three N. gonorrhoea isolates were included over the five 
years, of which only one showed resistance to ciprofloxacin. Ceftriaxone and cefixime, the third 
generation cephalosporins recommended in the GLASS antibiotic panel for testing, were not included 
in this study.  
GLASS metrics were consistent with the percentage resistance data and reinforced the existing 
literature which suggests that there is a decrease in the efficacy of older antibiotics such as ampicillin 
and trimethoprim-sulfamethoxazole and that emerging resistance to current treatment options is a 
grave concern as is the case with ciprofloxacin, third generation cephalosporins and carbapenems. 
The implication of the increasing resistance shown in the results, especially the prevalence of multi-
drug resistant infections, is that commonly encountered infections are becoming increasingly difficult 
to treat. Infections are responsive to a smaller range of broader spectrum antibiotics resulting in their 
increased use and subsequent selection pressure for resistance. If the current trends continue, 
untreatable infections will become more common, resulting in poorer clinical outcomes and higher 
mortality. It is clear that there is an urgent need to implement rational prescribing practices and 
infection control measures in order to curb the incidence and spread of antibiotic resistance. 
The standard treatment guidelines and the essential drugs list are devised and published by the South 
African National Department of Health for implementation in public health facilities. The aim of these 
guidelines is to streamline empiric drug therapy and encourage rational prescribing practices. Essack 
and Connolly carried out a study evaluating the sensitivity of antibiotics listed in the STGs against 
isolates from a district hospital, regional hospital and tertiary hospital, in Durban, South Africa. 
Susceptibility was found to be varied across different pathogen-drug combinations as well as between 
the different facilities. As such institution specific, evidence-based guidelines based on regular 
surveillance was recommended in order to improve the accuracy and success of empiric 
therapy.(19)The comparison between the trends in resistance and the antibiotics recommended in 
treatment guidelines showed >65% susceptibility in most pathogens to the recommended agents, with 
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the exception of K. pneumoniae in UTIs which showed 51 – 63% susceptibility to ciprofloxacin, 
gentamicin and amoxicillin-clavulanate  but only a 31% susceptibility to nitrofurantoin, the drug of 
choice for the treatment of UTIs in the 2nd and 3rd trimester of pregnancy and in patients with a severe 
penicillin allergy. Susceptibility in A. baumannii and K. pneumoniae from blood samples to 
gentamicin was between 30% and 40%. 
The data obtained during this study has provided a good overview of the trends in ABR in KwaZulu 
Natal, but the results may not be accurately representative of the true prevalence of resistance. As a 
retrospective study, the data obtained was limited by what had already been captured in the NHLS 
database, which only included results positive for microbial growth instead of all samples tested. In 
addition, due to technical problems data from one of the hospitals was missing for 2014. Many entries 
were excluded due to insufficient isolate or demographic data, which is an area for improvement in 
the routine capturing of AST results. Data was not stratified by demographic data such as age and 
gender; clinical data such as such as diagnosis and number of patient days and facility data such as 
hospital level and ward type. These parameters would be useful in providing a more detailed analysis 
of AMR and should be considered for future studies. The data obtained may also be misrepresentative 
as not all infections necessarily generate a sample for microbiological evaluations because of time and 
resource constraints and samples sent for AST are likely from patients who are severely ill and have 
experienced treatment failure.  Additionally, not all ill patients seek treatment due to difficulties in 
accessing healthcare as well as reliance on cultural healing methods. Only 6 public hospitals out of the 
71 provincial public hospitals in KwaZulu Natal were included in the study, meaning that community 
acquired infections and ABR in outlying regions of the province may not have been represented. 
Future studies should endeavour to include samples from community health settings, as well as try to 
include more hospitals so as to more accurately represent the status of ABR in KwaZulu Natal. 
While some pathogens showed a decline or plateau in resistance to the various antibiotics, the general 
trend observed is that of an increase in resistance to most of the antibiotics included in this study. This 
affirms the need for interventions to curb the incidence and spread of resistance such as better 
prescribing practices, using AST results to guide treatment and antibiotic stewardship. Resources are 
available to guide rational antibiotic prescribing including standard treatment guidelines published by 
the South African National Department of Health and other organisations but there is no guarantee 
that these recommendations are adhered to at ground level.  
This study highlights the potential for further research into the trends in resistance and it is apparent 
that resources are available to obtain the necessary isolates, AST results and demographic data as 
recommended by the WHO for the monitoring of ABR. This bodes well for the implementation of 
GLASS in South Africa, as we were able to calculate various metrics based on the GLASS 
recommendations and the overall analysis gave us a good indication of the general trends in antibiotic 
resistance in KZN. The ultimate goal of future studies would be to build on the existing knowledge 
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base and provide comparable, validated data which can be shared on a global scale in order to guide 
future interventions against the spread of ABR. 
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SUPPLEMENTARY DATA 
Table 1: Antibiotic Panel for AST Analysis per Pathogen  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pathogen Antibiotic Panel 
Acinetobacter baumannii Amikacin 
Colistin 
Ertapenem  
Gentamicin  
Imipenem 
Meropenem 
Tigecycline  
Escherichia coli Ampicillin 
Cefepime 
Cefotaxime  
Ceftazidime 
Ciprofloxacin  
Colistin 
Cotrimoxazole 
Ertapenem  
Imipenem 
Meropenem 
Klebsiella pneumoniae Cefepime 
Cefotaxime  
Ceftazidime 
Ciprofloxacin  
Colistin 
Cotrimoxazole 
Ertapenem  
Imipenem 
Meropenem 
Staphylococcus aureus Cefoxitin 
Shigella spp. Cefotaxime 
Ceftazidime 
Ciprofloxacin  
Streptococcus pneumoniae Cefotaxime 
Trimethoprim/sulfamethoxszole 
Penicillin G 
Salmonella spp. Cefotaxime 
Ceftazidime 
Ciprofloxacin  
Ertapenem  
Imipenem 
Meropenem 
 
Neisseria gonorhhoeae Ciprofloxacin 
Gentamicin 
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Table 2:  Overall AST Results between 2011 and 2015 per specimen type, pathogen and drug 
 
* CLSI Breakpoint not available 
** AM- Ampicillin, CIP- Ciprofloxacin, CTX- Cefotaxime, CAZ- Ceftazidime, FEP- Cefepime, IPM-   Imipenem, ETP- Ertapenem, MEM- 
Meropenem, CS- Colistin, SXT- Trimethoprim-sulfamethoxazole, GM- Gentamicin 
 
 
Bloodstream Infections 
 E. coli  K. pneumoniae  A. baumanii 
 MIC50 
(mg/l) 
MIC90 
(mg/l) 
Range n %R  
MIC50 
(mg/l) 
MIC90 
(mg/l) 
Range N %R  
MIC50 
(mg/l) 
MIC90 
(mg/l) 
Range n %R 
AM** ≥32 ≥32 ≤2 - ≥32 946 84.99  - - - - -  - - - - - 
CIP ≤ 0.25 ≥ 4 ≤0.25 - ≥8 953 28.54  1 ≥4 ≤0.25 - ≥8 1281 43.56  - - - - - 
CTX ≤1 ≥64 ≤1 - ≥64 934 27.52  ≥64 ≥64 ≤1- ≥64 1239 70.54  - - - - - 
CAZ ≤1 16 ≤1 - ≥64 934 17.56  16 ≥64 ≤1 - ≥64 1241 62.29  - - - - - 
FEP ≤1 8 ≤1 - ≥64 935 7.91  2 ≥64 ≤1 - ≥64 1229 26.53  - - - - - 
IPM ≤0.25 ≤1 ≤0.25 - ≥16 933 0.75  ≤0.25 ≤1 ≤0.25 - ≥16 1242 9.98  ≥16 ≥16 ≤0.25 - ≥16 745 63.33 
ETP ≤0.5 ≤0.5 ≤0.5 - 4 926 0.54  ≤0.5 ≤0.5 ≤0.5 - ≥8 1210 10,00  ≤0.5 ≥8 ≤0.5 - ≥8 * * 
MEM ≤0.25 ≤0.25 ≤0.25 - ≥16 914 0.55  ≤0.25 ≤0.25 ≤0.25 - ≥16 1169 8.55  ≥16 ≥16 ≤0.25 - ≥16 739 64.17 
CS ≤0.5 ≤0.5 ≤0.5 - ≥16 * *  ≤0.25 2 ≤0.25 - ≥16 * *  ≤0.5 2 ≤0.5-64 720 6.31 
SXT ≥320 ≥320 ≤10 - ≥320 951 78.13  ≥320 ≥320 ≤10 - ≥320 1279 76.54  - - - - - 
TGC - - - - -  - - -  -  1 2 ≤0.12 -  ≥8 * * 
GM - - - - -  - - -  -  ≥16 ≥16 ≤0.5 - ≥16 745 62.55 
AN - - - - -  - - -  -  8 32 ≤2 - ≥64 744 14.78 
 S. aureus  S. pneumoniae  Salmonella spp. 
 MIC50 
(mg/l) 
MIC90 
(mg/l) 
Range n %R  
MIC50 
(mg/l) 
MIC90 
(mg/l) 
Range N %R  
MIC50 
(mg/l) 
MIC90 
(mg/l) 
Range n %R 
CIP - - - - -  - - - - -  ≤0.25 ≤0.5 ≤0.25 - 2 230 25.65 
CTX - - - - -  ≤1 ≤1 ≤1 - 2 12 8.33  ≤1 ≤1 ≤0.5 - 4 173 2.89 
CAZ - - - - -  - - - - -  ≤1 ≤1 ≤1 - 4 169 0 
FEP - - - - -  - - - - -  - - - - - 
IPM - - - - -  - - - - -  ≤0.25 ≤1 ≤0.25 - 2 172 0.58 
ETP - - - - -  - - - - -  ≤0.5 ≤0.5 ≤0.5 - 1 172 2.33 
MEM - - - - -  - - - - -  ≤0.25 ≤0.25 ≤0.25 - 1 168 0 
CS - - - - -  - - - - -  - - - - - 
SXT - - - - -  ≤20 ≥320 ≤10 - ≥320 16 100 
 - - - - - 
FOX ≥64 ≥64 ≤4 - ≥64 * *  - - - - -  - - - - - 
OX1 - - - - -  ≤0.25 0.5 ≤0.25 - 0.5 * *  - - - - - 
P - - - - -   ≥0.5 4  ≥0.5 - 4 5 20  - - - - - 
                  
Urinary tract infections 
 E .coli  K. pneumoniae       
 MIC50 
(mg/l) 
MIC90 
(mg/l) 
Range n %R  
MIC50 
(mg/l) 
MIC90 
(mg/l) 
Range N %R       
SXT** ≥320 ≥320 ≤10 - ≥320 9431 72.27  ≥320 ≥320 ≤10 - ≥320 2890 64.98       
CIP ≤0.25 ≥4 ≤0.25 - ≥8 9445 31.69  ≤0.25 ≤4 ≤0.25 - ≥8 2893 37.33       
CAZ ≤1 16 ≤1 -  ≥64 9384 11.74  ≤1 ≥64 ≤1 - ≥64 2856 43.84       
CTX ≤1 ≥64 ≤1 - ≥64 9385 18.57  ≤1 ≥64 ≤1 - ≥64 2860 49.72       
FEP ≤1 ≤4 ≤1 - ≥64 9427 6.18  ≤1 32 ≤1 - ≥64 3017 20.23       
IPM ≤0.25 ≤1 ≤0.25 - ≥16 9386 0.6  ≤0.25 ≤1 ≤0.25 - ≥16 2859 4.06       
ETP ≤0.5 ≤0.5 ≤0.5 - ≥8 9370 0.6  ≤0.5 ≤0.5 ≤0.5 - ≥8 2837 5.11       
MEM ≤0.25 ≤0.25 ≤0.25 - ≥16 9184 0.5  ≤0.25 ≤0.25 ≤0.25 - ≥16 2789 4.73       
CS ≤0.5 ≤0.5 ≤0.5 - ≥16 * *  ≤0.5 1 ≤0.5 - ≥16 * *       
AM ≥32 ≥32 ≤2 - ≥32  9433 82.07  - - - - -       
Acute Diarrhoeal Infections 
 Salmonella spp.  Shigella spp.       
 MIC50 
(mg/l) 
MIC90 
(mg/l) 
Range n %R  
MIC50 
(mg/l) 
MIC90 
(mg/l) 
Range N %R       
CIP** ≤0.25 ≤0.5 ≤0.25 - ≥16 145 46.90  ≤0.25 ≤0.25 ≤0.25 - ≥4 319 0.94       
CTX ≤1 4 ≤1 - ≥64 156 11.54  ≤1 ≤1 ≤1 - ≥64 319 4.08       
CAZ ≤1 ≤1 ≤1 - ≥64 145 4.14  ≤1 ≤1 ≤1 - 16 319 0.31       
IPM ≤0.25 ≤1 ≤0.25 - ≤1 155 0,00  - - - - -       
ETP ≤0.5 ≤0.5 ≤0.5 - ≤1 156 7.05  - - - - -       
MEM ≤0.25 ≤0.25 ≤0.25 - ≤0.25 143 0,00  - - - - -       
Gonorrhoea 
 N. gonorrhoea             
 MIC50 MIC90 Range n %R             
CIP** ≤0.25 ≤0.5 ≤0.25 - ≤0.5 3 33.33             
GM ≤1 ≤1 ≤0.5 - ≤1 * *             
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Table 3: Proportion of non-susceptible samples out of all GLASS Pathogens per specimen type 
Proportion of non-susceptible samples out of all Blood samples positive for GLASS pathogens 
 
Blood: E. coli 2011 2012 2013 2014 2015   Overall 
  n %R n %R n %R n %R n %R P-
value 
n %R 
AM 125 6,98 149 6,23 191 6,77 133 9,83 206 6,13 0.000 804 6,86 
CAZ 16 0,89 32 1,34 28 0,99 25 1,85 63 1,87 0.007 164 1,40 
CIP 31 1,73 47 1,97 59 2,09 45 3,33 90 2,68 0.013 272 2,32 
CTX 22 1,23 48 2,01 49 1,74 45 3,33 93 2,77 0.000 257 2,19 
ETP 0 0,00 1 0,04 0 0,00 2 0,15 2 0,06 0.197* 5 0,04 
FEP 8 0,45 17 0,71 11 0,39 13 0,96 25 0,74 0.143 74 0,63 
IPM 0 0,00 3 0,13 0 0,00 0 0,00 4 0,12 0.131* 7 0,06 
MEM 0 0,00 2 0,08 1 0,04 0 0,00 2 0,06 0.818* 5 0,04 
SXT 128 7,14 150 6,27 181 6,41 123 9,09 161 4,79 0.000 743 6,34 
                            
Blood: K pneumoniae 2011 2012 2013 2014 2015   Overall 
  n %R n %R n %R n %R n %R P-
value 
n %R 
CAZ 71 3,96 121 5,06 174 6,16 150 11,09 257 7,64 0.000 773 6,59 
CIP 50 2,79 96 4,02 131 4,64 89 6,58 192 5,71 0.000 558 4,76 
CTX 82 4,58 152 6,36 189 6,70 168 12,42 283 8,42 0.000 874 7,46 
ETP 2 0,11 9 0,38 15 0,53 6 0,44 89 2,65 0.000* 121 1,03 
FEP 15 0,84 47 1,97 74 2,62 51 3,77 139 4,13 0.000 326 2,78 
IPM 2 0,11 12 0,50 14 0,50 5 0,37 91 2,71 0.000 124 1,06 
MEM 2 0,11 10 0,42 14 0,50 4 0,30 70 2,08 0.000* 100 0,85 
SXT 101 5,64 178 7,44 228 8,08 183 13,53 289 8,59 0.000 979 8,35 
                            
Blood: A. baumanii 2011 2012 2013 2014 2015   Overall 
  n %R n %R n %R n %R n %R P-
value 
n %R 
AN 17 0,95 31 1,30 35 1,24 11 0,81 16 0,48 0.007 110 0,94 
CS (ab) 6 0,33 11 0,46 12 0,43 10 0,74 8 0,24 0.161 47 0,40 
GM 71 3,96 114 4,77 140 4,96 69 5,10 72 2,14 0.000 466 3,98 
IPM (ab) 70 3,91 111 4,64 151 5,35 67 4,95 69 2,05 0.000 468 3,99 
MEM (ab) 69 3,85 112 4,68 151 5,35 69 5,10 61 1,81 0.000 462 3,94 
  2011 2012 2013 2014 2015   Overall 
Blood: S. aureus * * * * * * * * * *       
Blood: S. pneumoniae 2011 2012 2013 2014 2015   Overall 
  n %R n %R n %R n %R n %R P-
value 
n %R 
CTX 0 0,00 1 0,04 0 0,00 0 0,00 0 0,00 0.472* 1 0,01 
P (sp) 0 0,00 1 0,04 0 0,00 0 0,00 0 0,00 0.472* 1 0,01 
SXT 2 0,11 4 0,17 3 0,11 1 0,07 6 0,18 0.919* 16 0,14 
                  
Blood: Salmonella spp. 2011 2012 2013 2014 2015   Overall 
  n %R n %R n %R n %R n %R P-
value 
n %R 
CAZ 0 0,00 0 0,00 0 0,00 0 0,00 0 0,00 - 0 0,00 
CIP 4 0,22 20 0,84 26 0,92 7 0,52 2 0,06 0.000* 59 0,50 
CTX 5 0,28 0 0,00 0 0,00 0 0,00 0 0,00 0.000* 5 0,04 
ETP 4 0,22 0 0,00 0 0,00 0 0,00 0 0,00 0.001* 4 0,03 
IPM 1 0,06 0 0,00 0 0,00 0 0,00 0 0,00 0.268* 1 0,01 
MEM 0 0,00 0 0,00 0 0,00 0 0,00 0 0,00 - 0 0,00 
Total Blood stream infections caused 
by GLASS pathogens 
1792   2391   2823   1353   3363     11722   
                            
Proportion of non-susceptible samples out of all Urine samples positive for GLASS pathogens 
Urine: E. coli 2011 2012 2013 2014 2015   Overall 
  n %R n %R n %R n %R n %R P-
value 
n %R 
AM 924 32,91 1578 40,89 1879 42,22 1317 52,81 2044 30,97 0.000 7742 38,30 
CAZ 90 3,21 218 5,65 267 6,00 200 8,02 327 4,95 0.000 1102 5,45 
CIP 307 10,93 592 15,34 728 16,36 517 20,73 849 12,86 0.000 2993 14,81 
CTX 134 4,77 304 7,88 429 9,64 307 12,31 569 8,62 0.000 1743 8,62 
ETP 4 0,14 6 0,16 9 0,20 4 0,16 29 0,44 0.023* 52 0,26 
FEP 40 1,42 100 2,59 148 3,33 106 4,25 192 2,91 0.000 586 2,90 
IPM 8 0,28 12 0,31 15 0,34 5 0,20 16 0,24 0.816 56 0,28 
MEM 2 0,07 8 0,21 15 0,34 8 0,32 13 0,20 0.134* 46 0,23 
SXT 866 30,84 1429 37,03 1626 36,53 1156 46,35 1739 26,35 0.000 6816 33,72 
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Urine: K. pneumoniae 2011 2012 2013 2014 2015   Overall 
  n %R n %R n %R n %R n %R P-
value 
n %R 
CAZ 110 3,92 213 5,52 270 6,07 221 8,86 438 6,64 0.000 1252 6,19 
CIP 112 3,99 200 5,18 229 5,14 186 7,46 353 5,35 0.000 1080 5,34 
CTX 134 4,77 233 6,04 312 7,01 254 10,18 489 7,41 0.000 1422 7,04 
ETP 2 0,07 12 0,31 17 0,38 16 0,64 98 1,48 0.000* 145 0,72 
FEP 34 1,21 101 2,62 123 2,76 107 4,29 262 3,97 0.000 627 3,10 
IPM 4 0,14 8 0,21 6 0,13 13 0,52 85 1,29 0.000* 116 0,57 
MEM 4 0,14 6 0,16 16 0,36 14 0,56 92 1,39 0.000* 132 0,65 
SXT 222 7,91 341 8,84 411 9,23 335 13,43 569 8,62 0.000 1878 9,29 
                            
Total urinary tract infections caused 
by GLASS pathogens 
2808   3859   4451   2494   6600     20212   
                            
Proportion of non-susceptible samples out of all Faecal samples positive for GLASS pathogens 
Faeces: Salmonella spp. 2011 2012 2013 2014 2015   Overall 
  n %R n %R n %R n %R n %R P-
value 
n %R 
CAZ 3 2,94 2 1,41 0 0,00 0 0,00 1 0,37 0.010* 6 0,66 
CIP 5 4,90 13 9,15 34 14,35 7 4,29 9 3,31 0.000 68 7,42 
CTX 14 13,73 2 1,41 0 0,00 0 0,00 2 0,74 0.000* 18 1,97 
ETP 11 10,78 0 0,00 0 0,00 0 0,00 0 0,00 0.000* 11 1,20 
IPM 0 0,00 0 0,00 0 0,00 0 0,00 0 0,00 - 0 0,00 
MEM 0 0,00 0 0,00 0 0,00 0 0,00 0 0,00 - 0 0,00 
Faeces: Shigella spp. 2011 2012 2013 2014 2015       
  n %R n %R n %R n %R n %R   0 0,00 
CAZ 0 0,00 0 0,00 0 0,00 0 0,00 1 0,37 1.000* 1 0,11 
CIP 0 0,00 0 0,00 0 0,00 1 0,61 2 0,74 0.617* 3 0,33 
CTX 0 0,00 0 0,00 2 0,84 4 2,45 7 2,57 0.102* 13 1,42 
Total Acute Diarrhoeal infections 
caused by GLASS pathogens 
102   142   237   163   272 2,57   916   
                            
Proportion of non-susceptible samples out of all Urethral/cervical samples positive for GLASS pathogens 
N. gonorrhoea 2011 2012 2013 2014 2015   Overall 
  n %R n %R n %R n %R n %R P-
value 
n %R 
CIP (ng) 0 0,00 0 0,00 0 0,00 0 0,00 1 1.85 - 1 0,59524 
Total Gonorrhoeal infections  35   24   34   21   54     168   
 
Table 4: GLASS Population Measures 
1. GLASS Measure A1/B1: Number of infections caused by GLASS pathogens per specimen type per 100 000 inhabitants 
Specimen Type 2011 2012 2013 2014 2015 Overall p-value 
  n   n   n   n   N   n     
Blood 1792 17,45 2931 28,55 2823 27,50 1353 13,18 3363 32,75 12262,00 119,43 <0.001 
Urine 2808 27,35 3859 37,59 4451 43,35 2494 24,29 6600 64,28 20212,00 196,86 <0.001 
Faeces 102 0,99 142 1,38 237 2,31 163 1,59 272 2,65 916,00 8,92 <0.001 
Urethral/cervical 35 0,34 24 0,23 34 0,33 21 0,20 54 0,53 168,00 1,64 0,032 
                            
Population   10267300                       
                            
2. GLASS Measure B2: Number of Infections caused by GLASS pathogens per organism per 100000 inhabitants 
Blood  2011 2012 2013 2014 2015 Overall p-value 
 E. coli 397 3,87 441 4,30 417 4,06 221 2,15 609 5,93 2085,00 20,31 <0.001 
 K. pneumoniae 373 3,63 577 5,62 698 6,80 358 3,49 1053 10,26 3059,00 29,79 <0.001 
 A. baumanii 248 2,42 341 3,32 483 4,70 147 1,43 353 3,44 1572,00 15,31 <0.001 
S. aureus 543 5,29 773 7,53 890 8,67 471 4,59 1110 10,81 3787,00 36,88 <0.001 
S. pneumoniae 188 1,83 179 1,74 238 2,32 118 1,15 170 1,66 893,00 8,70 <0.001 
Salmonella spp 43 0,42 80 0,78 97 0,94 38 0,37 68 0,66 326,00 3,18 0,001 
                            
Urine 2011 2012 2013 2014 2015 Overall p-value 
E. coli  2202 21,45 2936 28,60 3257 31,72 1907 18,57 4913 47,85 15215,00 148,19 <0.001 
K. pneumoniae 606 5,90 923 8,99 1194 11,63 587 5,72 1687 16,43 4997,00 48,67 <0.001 
                            
Faeces 2011 2012 2013 2014 2015 Overall p-value 
Salmonella spp 47 0,46 46 0,45 78 0,76 46 0,45 82 0,80 299,00 2,91 0,111 
61 
Shigella spp 55 0,54 96 0,94 159 1,55 117 1,14 190 1,85 617,00 6,01 0,001 
                            
Urethral/cervical 2011 2012 2013 2014 2015 Overall p-value 
 N. gonorrhoea 35 0,34 24 0,23 34 0,33 21 0,20 54 0,53 168,00 1,64 0,032 
Population   10267300                       
                            
                            
3. GLASS Measure B3: Number of Resistant infections per pathogen and drug per 100 000 inhabitants 
Blood: E coli 2011 2012 2013 2014 2015 Overall p-value 
AM 125 1,22 149 1,45 191 1,86 133 1,30 206 2,01 804,00 7,83 <0.001 
CAZ 16 0,16 32 0,31 28 0,27 25 0,24 63 0,61 164,00 1,60 0,001 
CIP 31 0,30 47 0,46 59 0,57 45 0,44 90 0,88 272,00 2,65 <0.001 
CTX 22 0,21 48 0,47 49 0,48 45 0,44 93 0,91 257,00 2,50 <0.001 
ETP 0 0,00 1 0,01 0 0,00 2 0,02 2 0,02 5,00 0,05 0,175 
FEP 8 0,08 17 0,17 11 0,11 13 0,13 25 0,24 74,00 0,72 0,094 
IPM 0 0,00 3 0,03 0 0,00 0 0,00 4 0,04 7,00 0,07 0,164 
MEM 0 0,00 2 0,02 1 0,01 0 0,00 2 0,02 5,00 0,05 0,820 
SXT 128 1,25 150 1,46 181 1,76 123 1,20 161 1,57 743,00 7,24 <0.001 
Blood: K pneumoniae 2011 2012 2013 2014 2015 Overall p-value 
CAZ 71 0,69 121 1,18 174 1,69 150 1,46 257 2,50 773,00 7,53 <0.001 
CIP 50 0,49 96 0,94 131 1,28 89 0,87 192 1,87 558,00 5,43 0,002 
CTX 82 0,80 152 1,48 189 1,84 168 1,64 283 2,76 874,00 8,51 <0.001 
ETP 2 0,02 9 0,09 15 0,15 6 0,06 89 0,87 121,00 1,18 <0.001 
FEP 15 0,15 47 0,46 74 0,72 51 0,50 139 1,35 326,00 3,18 <0.001 
IPM 2 0,02 12 0,12 14 0,14 5 0,05 91 0,89 124,00 1,21 <0.001 
MEM 2 0,02 10 0,10 14 0,14 4 0,04 70 0,68 100,00 0,97 <0.001 
SXT 101 0,98 178 1,73 228 2,22 183 1,78 289 2,81 979,00 9,54 <0.001 
Blood: A. baumanii 2011 2012 2013 2014 2015 Overall p-value 
AN 17 0,17 31 0,30 35 0,34 11 0,11 16 0,16 110,00 1,07 0,223 
CS (ab) 6 0,06 11 0,11 12 0,12 10 0,10 8 0,08 47,00 0,46 0,067 
GM 71 0,69 114 1,11 140 1,36 69 0,67 72 0,70 466,00 4,54 <0.001 
IPM (ab) 70 0,68 111 1,08 151 1,47 67 0,65 69 0,67 468,00 4,56 <0.001 
MEM (ab) 69 0,67 112 1,09 151 1,47 69 0,67 61 0,59 462,00 4,50 <0.001 
Blood: S. aureus * * * * * * * * * *       
Blood: S. pneumoniae 2011 2012 2013 2014 2015 Overall p-value 
CTX 0 0,00 1 0,01 0 0,00 0 0,00 0 0,00 1,00 0,01 0,523 
P (sp) 0 0,00 1 0,01 0 0,00 0 0,00 0 0,00 1,00 0,01 0,523 
SXT 2 0,019 4 0,04 3 0,03 1 0,01 6 0,06 16,00 0,16 0,392 
Blood: Salmonella spp 2011 2012 2013 2014 2015 Overall p-value 
CAZ 0 0,00 0 0,00 0 0,00 0 0,00 0 0,00 0,00 0,00 NC 
CIP 4 0,04 20 0,19 26 0,25 7 0,07 2 0,02 59,00 0,57 <0.001 
CTX 5 0,05 0 0,00 0 0,00 0 0,00 0 0,00 5,00 0,05 <0.001 
ETP 4 0,04 0 0,00 0 0,00 0 0,00 0 0,00 4,00 0,04 <0.001 
IPM 1 0,01 0 0,00 0 0,00 0 0,00 0 0,00 1,00 0,01 0,248 
MEM 0 0,00 0 0,00 0 0,00 0 0,00 0 0,00 0,00 0,00 NC 
Urine: E. coli 2011 2012 2013 2014 2015 Overall p-value 
AM 924 9,00 1578 15,37 1879 18,30 1317 12,83 2044 19,91 7742,00 75,40 <0.001 
CAZ 90 0,88 218 2,12 267 2,60 200 1,95 327 3,18 1102,00 10,73 <0.001 
CIP 307 2,99 592 5,77 728 7,09 517 5,04 849 8,27 2993,00 29,15 <0.001 
CTX 134 1,31 304 2,96 429 4,18 307 2,99 569 5,54 1743,00 16,98 <0.001 
ETP 4 0,04 6 0,06 9 0,09 4 0,04 29 0,28 52,00 0,51 0,018 
FEP 40 0,39 100 0,97 148 1,44 106 1,03 192 1,87 586,00 5,71 <0.001 
IPM 8 0,08 12 0,12 15 0,15 5 0,05 16 0,16 56,00 0,55 0,788 
MEM 2 0,02 8 0,08 15 0,15 8 0,08 13 0,13 46,00 0,45 0,108 
SXT 866 8,43 1429 13,92 1626 15,84 1156 11,26 1739 16,94 6816,00 66,39 <0.001 
Urine: K. pneumoniae 2011 2012 2013 2014 2015 Overall p-value 
CAZ 110 1,07 213 2,07 270 2,63 221 2,15 438 4,27 1252,00 12,19 <0.001 
CIP 112 1,09 200 1,95 229 2,23 186 1,81 353 3,44 1080,00 10,52 <0.001 
CTX 134 1,31 233 2,27 312 3,04 254 2,47 489 4,76 1422,00 13,85 <0.001 
ETP 2 0,02 12 0,12 17 0,17 16 0,16 98 0,95 145,00 1,41 <0.001 
FEP 34 0,33 101 0,98 123 1,20 107 1,04 262 2,55 627,00 6,11 <0.001 
IPM 4 0,04 8 0,08 6 0,06 13 0,13 85 0,83 116,00 1,13 <0.001 
MEM 4 0,04 6 0,06 16 0,16 14 0,14 92 0,90 132,00 1,29 <0.001 
SXT 222 2,16 341 3,32 411 4,00 335 3,26 569 5,54 1878,00 18,29 <0.001 
Faeces: Salmonella 
spp. 
2011 2012 2013 2014 2015 Overall p-value 
CAZ 3 0,03 2 0,02 0 0,00 0 0,00 1 0,01 6,00 0,06 0,056 
CIP 5 0,05 13 0,13 34 0,33 7 0,07 9 0,09 68,00 0,66 <0.001 
CTX 14 0,14 2 0,02 0 0,00 0 0,00 2 0,02 18,00 0,18 <0.001 
62 
ETP 11 0,11 0 0,00 0 0,00 0 0,00 0 0,00 11,00 0,11 <0.001 
IPM 0 0,00 0 0,00 0 0,00 0 0,00 0 0,00 0,00 0,00 NC 
MEM 0 0,00 0 0,00 0 0,00 0 0,00 0 0,00 0,00 0,00 NC 
Faeces: Shigella spp. 2011 2012 2013 2014 2015 Overall p-value 
CAZ 0 0,00 0 0,00 0 0,00 0 0,00 1 0,01 1,00 0,01 1,000 
CIP 0 0,00 0 0,00 0 0,00 1 0,01 2 0,02 3,00 0,03 0,646 
CTX 0 0,00 0 0,00 2 0,02 4 0,04 7 0,07 13,00 0,13 0,152 
N. gonorrhoea 2011 2012 2013 2014 2015 Overall p-value 
CIP (ng) 0 0,00 0 0,00 0 0,00 0 0,00 1 0,01 1,00 0,01 NC 
Population   10267300                       
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CHAPTER 3: CONCLUSION, LIMITATIONS AND RECOMMENDATIONS 
3.1 Conclusion 
A retrospective analysis of trends in antibiotic resistance (ABR) was conducted on data obtained from 
six public hospitals in KwaZulu Natal. The specimen types, pathogens and antibiotics included in the 
study were based on the guidelines published in the GLASS manual for early implementation. MIC 
and percentage resistance data was compiled for priority pathogens from blood, urine, faecal and 
urethral/ cervical samples representing blood stream infections (BSIs), urinary tract infections (UTIs), 
acute diarrhoeal infections and gonorrhoeal infections. The antibiotic resistance data was stratified by 
year and analysed on 3 levels: (1) a trend analysis of resistance including MIC50, MIC90, MIC ranges 
and percentage resistance over 5 years was conducted; (2) selected metrics recommended in the 
GLASS manual were calculated and (3) susceptibility data was compared with existing standard 
treatment guidelines.   
The following were the main conclusions in relation to the aim and objectives: 
1. A database of BSIs, UTIs, diarrhoeal infections and gonorrhoeal infections was generated 
including specimen type, isolate identification and AST data. 
2. The proportion of BSIs, UTIs and diarrhoeal infections caused by the respective pathogens of 
interest were summarised as follows: 
o Urine samples accounted for 61% (n= 33 018) of all isolates included in the study 
o E. coli from blood and urine samples was the most commonly isolated pathogen 
(52%, n= 33 018)  
o Of the 11 722 positive blood samples, the most common causative pathogens were S. 
aureus (32%), K. pneumoniae (26%) and E. coli (18%). 
o Of the 20 212 positive urine samples, the most common causative pathogens were E. 
coli (75%) followed by K. pneumoniae (25%). 
o Of the 916 stool samples, the most common causative pathogens were Shigella spp. 
(67%) and Salmonella spp. (33%) 
o Only 168 gonorrhoeal infections were explored over the 5year period. 
 
3. The trends in resistance between 2011 and 2015 were as follows: 
o The majority of isolates were multi-drug resistant 
o Resistance to third and fourth generation cephalosporins and fluoroquinolones 
increased in K. pneumoniae, E. coli and Shigella spp. isolates as did carbapenem 
resistance in K. pneumoniae and E. coli. 
o Resistance in A. baumannii and Salmonella spp. isolates decreased or plateaued 
against all antibiotics. 
4. In terms of standard treatment guidelines: 
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o BSIs: Treatment guidelines were only available for S. aureus. Susceptibility to 
vancomycin was 97% (n= 1368) 
o Only 50 – 68%% of UTIs were treatable with the first line agents ciprofloxacin and 
amoxicillin-clavulanate.  
o Seventy-five percent and 99% of the 145 and 319 diarrhoeal infections caused by 
Salmonella spp. and Shigella spp. could be have been successfully treated with 
ciprofloxacin  
3.2. Limitations: 
5. Antibiotic susceptibility data was only available for samples positive for bacterial growth. 
6. Only 6 out of 71 public hospitals in KwaZulu Natal were included in the study. 
7. Available data did not allow stratification into community and hospital acquired infections. 
8. As a retrospective study, the data was limited to what was already captured in the National 
Health Laboratory Services (NHLS) database 
9. The results may not be representative of the true extent of ABR in KwaZulu Natal as not all 
infections necessarily generate a sample for microbiological evaluations because of time and 
resource constraints.  Additionally, not all ill patients seek treatment due to difficulties in 
accessing healthcare as well as reliance on cultural healing methods.  
10. The data was collected before the release of the GLASS manual by the WHO and therefore 
does not meet all the requirements stipulated therein. 
 
3.3. Recommendations: 
 Robust, representative surveillance is necessary to establish a baseline of ABR in KwaZulu 
Natal and South Africa. 
 More facilities should be included in future studies including community health centres and 
private facilities in order for data to be accurately representative of the true extent of ABR in 
community and hospital settings. 
 Data capturing standards should be improved to minimise the number of entries that had to be 
excluded and to allow better correlation of demographic and clinical data with resistance 
trends. 
 Standard treatment guidelines should be informed by surveillance data to ensure the efficacy 
of empiric treatment. 
 Increasing resistance to cephalosporins and fluoroquinolones, which are commonly used in 
the treatment of infections caused by E. coli, K. pneumoniae, Salmonella spp. and Shigella 
spp., should be monitored and the treatment guidelines modified according to latest 
surveillance data. 
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 The increasing incidence of carbapenem resistance, especially in K. pneumoniae, should be 
monitored. 
 
3.4. Significance: 
 To our knowledge, this is the first South African report on ABR using GLASS metrics.    
 This study implemented the GLASS methodology and is therefore an indication of the 
capacity to implement surveillance according to these standards in South Africa. 
Shortcomings of this study can be used to improve the design of future studies so that better 
quality and representative data can be obtained. 
 According to the 2014 WHO report on surveillance, data on ABR in the Africa region is 
scarce and there is limited evidence available on the true extent of ABR in the region (World 
Health Organisation, 2014). This study somewhat addresses this surveillance gap in a single 
province of KwaZulu-Natal in South Africa.   
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